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xi
The birth of complexity research derives from the logical progression of advancement in
the scientific field afforded by reductionist theory. We present in silico models of two
complex physiological processes, wound healing and coagulation/fibrinolysis based on
two common tools in the study of complex physiology: ordinary differential equations
(ODE) and Agent Based Modeling (ABM). The strengths of these two approaches are
well-suited in the analysis of clinical paradigms such as wound healing and coagulation.

The complex interactions that characterize acute wound healing have stymied the
development of effective therapeutic modalities. The use of computational models holds
the promise to improve our basic approach to understanding the process. We have
modified an existing ordinary differential equation model by 1) evolving from a systemic
model to a local model, 2) the incorporation of fibroblast activity, and3) including the
effects of tissue oxygenation. Possible therapeutic targets, such as fibroblast death rate
and rate of fibroblast recruitment have been identified by computational analysis. This
model is a step toward constructing an integrative systems biology model of human
wound healing.

The coagulation and fibrinolytic systems are complex, inter-connected biological systems
with major physiological roles. We present an Agent Based Modeling and Simulation
(ABMS) approach to these complex interactions. This ABMS method successfully
reproduces the initiation, propagation, and termination of blood clot formation and its
lysis in vitro due to the activation of either the intrinsic or extrinsic pathways.
Furthermore, the ABMS was able to simulate the pharmacological effects of two
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clinically used anticoagulants, warfarin and heparin, as well as the physiological effects
of enzyme deficiency/dysfunction, i.e., hemophilia and antithrombin III-heparin binding
impairment, on the coagulation system. The results of the model compare favorably with
in vitro experimental data under both physiologic and pathophysiologic conditions.

Our computational systems biology approach integrates reductionist experimental data
into a cohesive model that allows rapid evaluation of the effects of multiple variables.
Our ODE and AMBS models offer the ability to generate non-linear responses based on
known relationships among variables and in silico modeling of mechanistic biological
rules on computer software, respectively. Simulations of normal and disease states as
well as effects of therapeutic intervention demonstrate the potential uses of computer
simulation. Specifically, models may be applied to hypothesis generation and biological
advances, discovery of new diagnostic and therapeutic options, platforms to test novel
therapies, and opportunities to predict adverse events during drug development. The
ultimate aim of such models is creation of bedside simulators that allow personalized,
individual medicine; however, a myriad of opportunities for scientific advancement are
opened through in silico experimentation.

1

Introduction
Complexity Theory
Classic scientific approach suggests that the universe may be understood through the study of its
individual components, i.e. reductionism[1,2]. Through deconstruction of complex problems
into their integral parts, the reductionist approach successfully predicts those outcomes perfectly
explained through simple mechanistic behaviors. This approach predefines the system as one
composed of simple relationships between individual components, unaffected by the properties
of the system itself; single causes result in single effects with small perturbations of the system
as a whole. Particle physics and molecular biology are examples of fields that have made
enormous gains through reductionist analysis. In contrast, complex systems resist
characterization in this manner.

A system is a delineated part of the universe which is distinguished from the rest by a real or
imagined boundary. Systems may be characterized as open/closed and simple/complex. Closed
systems are maintained by internal forces and are not influenced by external forces. Open
systems, which are commonly found in biology, are in permanent interaction with their
environment. Therefore, in order to understand an open system you must describe the system, its
environment, and the interactions between them. Simple systems have single cause and effect,
small change in cause results in small change in effect, thereby predictable. Complex systems
have circular causality, feedback loops, logical paradoxes and/or strange loops; small changes in
cause have the potential to cause large effects, thereby displaying emergence phenomena and
making them unpredictable[3]. In order to account for these multifactorial characteristics, the
system approach attempts to combine both the reductionist and holistic approaches. Complex
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systems analysis endeavors to explain how simple entities without any central controller and
limited communication can combine to form complicated and sophisticated systems. By
definition, complex systems exhibit emergent and self-organized behavior. Adaptive, non-linear
behavior may arise from seemingly small changes in initial conditions. Unlike systems defined
by linear relationships, initial conditions cannot predict the magnitude or direction of the
outcome. Thus, newer methods such as chaos theory, evolutional economics and network theory
have evolved to explain complex systems such as weather/climate, societal behavior, and disease
states of living organisms[4].

Analysis of complex systems requires an all-inclusive approach that acknowledges its
heterogeneous components and processes. Temporal and spatial variability are integrated as
multiple cause/effect mechanisms may occur simultaneously. The following critical properties
are addressed first and foremost: 1) self-organization, i.e. no overriding controller, 2) non-linear
relationships, and 3) emergence. This analysis is further complicated by potential emergence of
component parts. A complex system may, in and of itself, be formed from a series of complex
systems. For example, individual organs (heart, brain, liver, etc…) are complex systems that
contribute to the behavior of the organism as a whole. In fact, each individual cell is also a
complex system.

The collective action of a complex system integrates the internal and external environment in a
unique manner delineated through the properties within the system. Interactions such as
feedback loops, feedforward loops, circular causality, and self-organization result in emergence,
whereby simple components produce complex behavior[5]. Through circular causality, the
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sequence of cause and effects lead back to the initiating event in a manner that confirms or
changes the initial circumstance (AB CA). Feedback implies a loop whereby the product
returns and affects the input. Negative feedback reduces the deviation from a goal state
(stabilization effects). Positive feedback increases the deviation from an initial state
(destabilizing). Prediction of this behavior does not follow from the reductionist model of
characterization of the individual components. Dissection of these systems into its components
mislays the complex behavior under investigation. As a result, reductionist theory is unable to
predict the behaviors of a system with emergent properties. A hurricane results from a series of
conditions involving pressure, condensation, and temperature gradients. A living organism
produces complex physiology/behavior from the local actions of cells.

Unique properties emerge as a result of heterogeneous components interacting in a non-linear
manner. Nonlinear systems may show sensitivity to initial conditions where a small change in a
variable may cause a large effect in the outcome of the system. Conversely, vastly different
initial conditions may generate non-unique solutions. The systems show both time and state
dependence in that they depend on not only the current state of the system, but also historical
events. The most important property of such systems is that they display emergent behaviors
that cannot be predicted from analysis of the individual components. In biological systems,
emergent behaviors often result in highly ordered and stable systems. Complexity science
suggests that life is in accordance with the laws of physics, but physics first principles alone
cannot predict life[6]. A more complete understanding of a system requires holism. The holistic
approach focuses on organizational principles where the emergent properties of a system arise
from the interactions of its parts.
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In short, a complex nonlinear system may be viewed as a system consisting of an extremely large
and variable number of components. These components are capable of displaying significant
temporal and spatial variability but, at the same time, can retain a high degree of interdependence
between each other. What we learn from this is that topology and dynamics interact to produce
system behaviors. Thus, it is the combination of the dynamics of the various components
themselves and the relationship or connections (nature and degree) between the components,
which emerge as being of utmost importance. A complex system renders distinction between
cause and effect relatively meaningless as the dynamic relationship among components results in
effects modifying causes to create new, independent outcomes.

By definition, a complex system is one that satisfies certain critical properties. First, it is
composed of many parts that are coupled in a nonlinear fashion with no overlying controller that
determines the behavior of the system (the system must be self-organizing). Second, the system
must show emergence. That is, the whole system must contain properties that are unpredictable
from the parts/component pieces of the network or system. Typically, in such systems, as the
number of components and their relationships increase, the complexity also increases. As a
result of the spatio-temporal relationships of the system, the system may exhibit a variety of
dynamical behaviors from stable flows to seemingly random oscillations. Complex systems may
demonstrate many other dynamical behaviors. Possible behaviors include sensitivity to initial
conditions where a small change in a variable may oftentimes cause a large effect in the
dynamical outcome of the system (butterfly effect)[7]. Other properties include hysteresis, a
property in which model parameter sets may generate non-unique solutions with the same initial
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parameter conditions, and bifurcation dynamics where radically different behaviors such as
going from stable to unstable or stable to oscillatory may occur over very small parametric
ranges[8,9]. Spatial and temporal patterns can exhibit properties of self-similarity (fractality) in
which changes in scale visualization of the pattern show no alteration in the basic structure of the
pattern itself[10,11]. Systems can exhibit self-organization and coalescence, evolution and
adaptation[12]. Finally, system dynamics may contain n historical component in which the
temporal dynamics of the system, at a particular time point, is partially or fully dependent upon
the prior history (dynamical behaviors) of the system or its components.

Reductionist approaches dissect systems in order to better understand its' nature. However, one
of the fundamental properties of synergistic complex systems is that subfractionation can and
does cause a loss of information (structural, relational, temporal and hierarchical). Subsequently,
destruction of emergent properties that are not contained within the subfraction pieces occurs.
Despite the fact that upper level hierarchical structures may contain a super emergent dynamics
set, sub-levels may contain their own emergent dynamics that are not necessarily seen until the
sub-level is separated from the whole system. One must be clear that sublevel emergence is
potentially artifactual due to the breaking of links to the whole system. These emergent
properties are always present in the whole system but are invisible and cannot be appreciated
from a reductionist approach. Thus, we cannot dissect a complex system in the parts, study them
and expect to fully understand the system. Dissection of the overall system destroys the
important ingredient of semantics-syntax, context dependence, and self-reference; properties that
are vital in the production of emergent behaviors. To summarize, complex systems are
composed of many components connected in a non-linear manner, must be self organizing, no
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overlying controller, must show emergence, and contains properties that are unpredictable from
the individual components of the system. As a result of these properties, a complex system
cannot be dissected and studied as individual components.

Examples of complex systems are found throughout the natural world[13]. As described above,
climate, human behavior, and disease processes all exhibit complex function[14,15]. These
examples may be further subdivided or expanded into additional complex systems. Climates are
complex systems that affect the emergent behavior of ecosystems. Within ecosystems, complex
behavior is exerted through herd mentality, the eruption of a volcano, the gathering patterns of
ants and bees[16].

Humans behave in a complex manner, from flight patterns to societal organization of economies
and politics to the functioning of the internet[17,18,19]. The integration of numerous individual
and societal relationships in the United States results in the election of a president[3].
Combinations of supply and demand produce economic outcomes that differ from predicted
linear relationships.

Medical and biological processes are a field of acute interest for complex systems analysis[20].
Individual organs and their inherent functions produce complex behavior, as does their
interaction as a whole. Heart rate variability, immune system response, and phenotypic variation
result from disparate inputs[21,22]. In this manner, biologic complexity defies reductionist
patterns of recognition[23]. As most disease states result from dysfunction of complex systems,
newer methods of analysis offer an innovated, personalized approach currently lacking in the
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biomedical sciences. Herein, emergent properties of pathophysiological states of wound healing
and coagulation/fibrinolysis are characterized. A series of in silico experiments using ordinary
differential equations (ODEs) and agent based modeling (ABM) demonstrates the potential
application of a systems biology approach in these disease states.

Biologic Complexity
Wound Healing - The normal response to tissue injury is a timely and orderly reparative process
that results in sustained restoration of anatomic and functional integrity[24]. In contrast, in
chronic dermal ulcers the healing process is prolonged, incomplete, and proceeds in an
uncoordinated manner resulting in poor anatomical and functional outcome. On the opposite end
of the spectrum are the numerous clinical problems associated with excessive healing and
fibrosis. Clinically, wounds can be categorized as acute or chronic based on the timeliness of
healing[25].

Wound repair is a complex process involving a highly regulated cascade of events requiring
interactions among many cell types, soluble factors, and matrix components[26]. There are four
distinct phases of acute wound healing consisting of hemostasis, inflammation, proliferation, and
remodeling. Following injury, exposure of platelets to the extracellular matrix (ECM) induces
them to adhere and aggregate, thus, releasing the contents of their secretory granules. This
hemostasis response occurs immediately following tissue disruption and is needed to control
bleeding and seal the site of injury. The wide variety of platelet factors liberated by
degranulation include those which facilitate hemostasis and also act as chemoattractants [platelet
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derived growth factor (PDGF) and transforming growth factor beta (TGF-B)] for cells involved
in the next stage of repair, the inflammatory phase.

The process of hemostasis begins immediately upon injury. The immediate goal is to stabilize
the wound and thereby prevent exsanguination. Exposed blood vessels vasoconstrict and
platelets that are exposed to collagen are activated and begin the process of aggregation at the
wound site. These activated platelets release growth factors, cyclic adenosine monophosphate
(cAMP), and adhesive glycoproteins, which in turn activate receptors that cause platelets to
become sticky and aggregate. The glycoproteins released from activated platelet alpha granules,
include fibrinogen, fibronectin, thrombospondin, and von Willebrand factor. The next step in
hemostasis involves the coagulation cascade as coagulation factors from the blood combine with
coagulation factors released by platelets. The result is a fibrin clot that not only prevents further
blood loss, but also serves as a provisional wound healing matrix[27]. Platelets become
entrapped in the fibrin clot providing further bulk as well as a membrane on which inactive
clotting enzymes are bound and activated further promoting the clotting cascade.

Growth factors released by the platelet alpha granules provide the impetus for the next stage in
wound healing. Neutrophils and monocytes are recruited and activated by PDGF and TGF-B.
Endothelial cells are activated by vascular endothelial growth factor (VEGF), transforming
growth factor alpha (TGF-a), and basic fibroblast growth factor (bFGF). Fibroblasts are
activated by PDGF to begin migration to the wound site and produce collagen and
glycosaminoglycans, which facilitates cellular migration and interactions with the cell matrixsupporting framework. In addition to factors released from platelets, breakdown fragments from
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complement, such as C5a and f-Met-Leu-Phe, a bacterial waste product, also signal and recruit
neutrophils to the wound site. In sum, hemostasis initiates the wound healing response through
platelet activation at the site of the injury, and the interactions of soluble mediators and growth
factors with the ECM to provide the provisional wound healing matrix that sets the stage for
subsequent events.

The inflammatory phase begins as early as 2 h after injury. Activated neutrophils leave the
circulation to begin the debridement of devitalized tissue and phagocytosis of any infectious
agents or foreign bodies. Neutrophils also secrete cytokines and other specific chemical
„„signals‟‟ needed to attract specialized cells that are important in repairing the injured
tissue. In addition, neutrophils release a battery of proteolytic enzymes, such as elastase and
matrix metalloproteinase-8 (MMP-8), to assist in their movement through the tissue and remove
damaged ECM[28,29,30]. Mast cell granules are filled with enzymes, such as chymase and
tryptase, histamine, and other active amines; when released these enzymes cause the classic signs
of inflammation: rubor (redness), calor (heat), tumor (swelling), and dolor (pain). The crucial
inflammatory cells during the inflammatory phase are neutrophils and activated monocytes
(macrophages). Neutrophils and macrophages are responsible for bound wound bed preparation
and the initial milieu of the healing wound. In order to expedite healing, cellular debris and
bacteria are cleared. The inflammatory cells also release cytokines [including interleukins 1 (IL1), IL-6, IL-8, and tumor necrosis factor alpha (TNF-a)] and growth factors [PDGF, TGF-B,
TGF-a, insulin-like growth factor-1(IGF-1), and FGF] that not only serve to continue the
inflammatory phase but also initiate the proliferative phase by recruiting fibroblasts and
epithelial cells.
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In the first 24 h, neutrophils are the predominant inflammatory cell type. The neutrophils are
recruited and activated by the soluble mediators released by platelets and the coagulation cascade
during the hemostatic phase. The initial goal of the neutrophils is to prepare the wound bed by
killing bacteria and removing devitalized tissue. Not only does this begin the process of
wound healing but also helps fight infection. Neutrophils are chemoattracted to the wound site
by the initial inflammatory cytokines released at the time of injury and subsequent hemostasis
process. Normally, the weak adherence of leukocytes results in a rolling type motion along the
surface of the endothelial cells. The slower velocity allows more time for binding between the
adhesion molecules [selectins, cell adhesion molecules (CAMs), and cadherins] and receptors
(integrins) of circulating leukocytes and vascular endothelial cells. Once activated, leukocytes
firmly adhere to epithelial cells as a result of the binding between integrin receptors and ligands,
such as vascular CAM (VCAM) and intercellular adhesion molecule (ICAM), which are
expressed on activated endothelial cells. The activated leukocytes are induced to migrate
between the endothelial cells and move into the injured tissue using their integrin receptors to
bind to ECM components. At that point, inflammatory cells secrete elastase and collagenase in
order to migrate through the basement membrane of the endothelial cell and into the ECM. Once
the neutrophils have entered the wound, they begin to phagocytose bacteria and subsequently
produce oxygen free radical to kill the entrapped bacteria. In addition, they degrade damaged
components of the ECM by releasing large amounts of proteases (neutrophil elastase and
neutrophil collagenase). Neutrophils also produce and release inflammatory mediators, such as
TNF-a and IL-1, which further recruit and activate more neutrophils as well as fibroblasts and
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epithelial cells. After 2–3 days, neutrophils are no longer the dominant cell type as they are
depleted by apoptosis allowing tissue monocytes to predominate.

After the first 24 h, activated monocytes (macrophages) are the most numerous inflammatory
cell types present in the wound bed. Macrophages are not only active in healing the wound but
also in the regulation and progression of the healing process. Macrophages are mandatory
components of the normal healing process[31]. Circulating monocytes are attracted to the wound
site and extravasate in the same manner as described for neutrophils. Once the monocyte has
entered the wound site, they are activated into tissue macrophages by chemokines, cytokines,
growth factors, and soluble fragments of ECM components produced by proteolytic degradation
of collagen and fibronectin. Macrophages play a similar role as neutrophils in the healing
process. They are responsible for killing bacteria and wound debridement through the actions of
secreted MMPs and elastase. In addition to the functions shared with neutrophils, the
macrophages also play a crucial role in modulating the inflammatory response by regulating the
proteolytic destruction of wound tissue and initiating the transition from the inflammatory phase
to the proliferative phase. Macrophages downregulate tissue destruction by secretion of
inhibitors of the proteases. They also release a wide variety of growth factors and cytokines
including PDGF, TGF-B, TGF-a, FGF, IGF-1, TNF-a, IL-1, and IL-6 that serve to recruit and
activate fibroblasts and promote angiogenesis. The addition of fibroblasts that synthesize,
deposit, and organize the provisional ECM, combined with the ability to decrease proteolytic
destruction leads to the initiation of the proliferative phase. As the number of macrophages
decrease and the number of fibroblasts increase the wound begins to enter the proliferative phase
and exit the inflammatory phase.
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During the „„proliferation‟‟ phase, keratinocytes proliferate, migrate, and differentiate, thus,
restoring surface integrity. Endothelial cells from damaged blood vessels begin to send out new
capillary buds, while fibroblasts from nearby connective tissue enter the wound site and deposit
ECM[32]. In the normal dermis, fibroblasts are quiescent and have a low concentration, but in
granulation tissue and the provisional matrix of the wound they are active and exist in high
concentrations. Fibroblasts are recruited to the wound site by the soluble products of activated
platelets and macrophages. The migration of fibroblasts is far more complicated than that of
neutrophils and macrophages as they have to change their morphology and clear a path for their
movement from the ECM to the wound site.

Fibroblasts begin their migration by first binding to matrix components (fibronectin, vitronectin,
and fibrin) via their integrin receptors. The receptors bind to specific amino acid sequences (RG-D or arginine–glycine–aspartic acid) or binding sites on the matrix components. The
fibroblasts move in a step-wise pattern by extending a cytoplasmic projection from the unbound
side of its membrane to find the next binding site. Once a new site is successfully bound, the
original site is then released (by local protease activity), and the cell pulls itself forward using its
cytoskeleton network of actin fibers.

The concentration gradient provided by chemotactic growth factors, cytokines, and chemokines
in conjunction with the alignment of the fibrils in the ECM and provisional matrix determine the
direction of fibroblast migration. The fibroblast moves along the fibrils as opposed to across
them. The proteolytic enzymes used to facilitate their forward motion include collagenase
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(MMP-1), gelatinases (MMP-2 and MMP-9) that degrade gelatin substrates, and stromelysin
(MMP-3) that has multiple protein substrates in the ECM.

Collagen is the major ECM component providing strength, integrity, and structure to normal
tissues. It is also required to repair defects created by injuries, thereby restoring tissue structure
and function[32,33]. During repair, collagen is initially laid down in irregular bundles
possessing modest mechanical strength, but as the wound matures, the collagen is cross-linked
and then the scar undergoes remodeling indicating the „„maturation‟‟ phase of healing. The
collagen is then organized into a dense structure with increasing tensile strength as the matrix
begins the process of contraction. However, the regained tensile strength will never reach
normal; the maximum a wound can ever achieve is approximately 80% of normal tensile
strength[32,33]. Other components of the ECM that exhibit significant structural and functional
roles include fibronectin, laminin, proteoglycans, and glycosaminoglycans[34]. Fibronectin and
laminin contain important binding sites for cells, collagen, as well as glycosaminoglycans[35].

Wounds with significant tissue loss heal by the mechanism of contraction, a process whereby the
edges of a wound are drawn toward the center, due to forces generated within the wound.
Contraction facilitates spontaneous wound closure by reducing the volume required to be filled
by granulation tissue as well as the area required to be re-epithelized[33,36].

In order to protect the underlying wound it is necessary to create an epithelial barrier.
Epithelization is a complex process that involves epithelial cell detachment phenotypic
alterations, migration, proliferation, and then differentiation[37]. An undamaged mature
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epidermis consists of five layers of differentiated epithelial cells ranging from the cuboidal basal
keratinocytes nearest to the dermis up to the flattened, hexagonal, and tough keratinocytes in the
uppermost layer. Only one layer is capable of replication (the basal epithelial cells). These basal
cells are normally attached to their neighboring cells by intercellular connectors called
desmosomes and to the basement membrane by hemidesmosomes. In order to begin replicating
basal cells must become activated by growth factors such as EGF, keratinocyte growth factor
(KGF), and TGF-a. The growth factors bind to receptors on the epithelial cells and stimulate
migration and proliferation. In addition to the activation of basal cells, growth factors trigger the
desmosomes and hemidesmosomes to dissolve. Subsequently, cells may detach in preparation
for migration. Integrin receptors are then expressed and the normally cuboidal basal epithelial
cells flatten in shape and begin to migrate as a monolayer over the newly deposited granulation
tissue, following along collagen fibers. The monolayer is provided with new cells from the
proliferating basal cells near the wound margin (cells that are actively migrating are incapable of
proliferation). In order for the epithelial cells to penetrate the newly formed scab, necrotic tissue,
or escar, the leading edge of the monolayer produces and secretes proteolytic enzymes (MMPs).
The migration ceases after the epithelial cells contact each other. Once this contact has been
made, the entire epithelial monolayer forms a confluent sheet and enters a proliferative mode and
the stratified layers of the epidermis are reestablished and begin to mature to restore barrier
function. The intercellular desmosomes and the hemidesmosome attachments to the newly
formed basement membrane are also reestablished. TGF-B is one growth factor that can speed
up the maturation (differentiation and keratinization) of the epidermal layers. Clinically,
epithelialization is the hallmark of healing, but it is not the final event, as the granulation tissue
must be remodeled to form the permanent scar.
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During late phases of wound healing, scar remodeling involves a variety of matrix degrading
enzymes including MMPs, serine proteinases, cathepsins, and glycosidases[36,38]. The goal of
the remodeling phase is the conversion of the preliminary wound matrix to the production of a
final scar that maximizes wound tensile strength. Fibroblasts are the cells responsible for
remodeling. An equilibrium between collagen formation and degradation results in a constant
amount of collagen. There are several different classes of proteolytic enzymes in the wound bed
that are responsible for the degradation of collagen: MMPs, serine proteinases, cathepsins, and
glycosidases[36,38]. Specific MMP proteases required for remodeling include collagenases
(which degrade intact fibrillar collagen molecules), the gelatinases (which degrade damaged
fibrillar collagen molecules), and the stromelysins (which very effectively degrade
proteoglycans). The most important serine protease is neutrophil elastase, which can degrade
almost all types of protein molecules. In order to balance the destructive capabilities of the
matrix degrading enzymes, inhibitors are also needed. The specific inhibitors of the MMPs are
the tissue inhibitors of metalloproteinases (TIMPs) and specific inhibitors of serine protease are
a1-protease inhibitor (a1-PI) and a2-macroglobulin. The process of remodeling is dependent on
the relative activities of the proteases and their inhibitors.

Tightly controlled regulatory systems maintain a delicate balance between these complex
synthetic and degradative processes; normal tissue repair ultimately results from a fine-tuning of
this equilibrium. There is now a growing recognition that abnormal wound healing often results
from a disruption of degradative/synthesis equilibrium[29,30,39,40,41]. When the balance tips in

16

favor of matrix degradation, the end result may be a chronic ulcer, where as reduced degradation
and/or increased matrix synthesis results in fibrosis.

Research scientists and clinicians have focused historically on the effects of cytokines and
growth factors on individual cells in vitro, out of context of both the injury and the organism[42].
The relationships among the various cell types and the dynamics of the wound healing process
has remained uncharacterized. As a result, therapies to improve wound healing have either failed
or shown minimal improvements in outcomes. One possible reason for such failures is that the
complex, multi-scale, multi-temporal, hierarchical nature of wounds has thus far been
underappreciated. In order to account for these relationships, an overarching systems biological
approach would allow one to draw upon the nuanced methodologies of complexity
theory[43,44]. Fueled by the ongoing identification of numerous inflammatory and immune
mediators produced in the normal response to acute soft tissue injury, ample evidence of this
oversimplification can be found in the failure of single mediator-targeted therapies. Many
features of the wound healing process are consistent with complexity theory: 1) Multiple cell
types interact using paracrine and autocrine signaling (signals may be amplified/dampened
based on the state and history of the individual cell in a non-linear manner) 2) There is no
overlying control mechanism 3) The process of wound healing progresses through hemostasis,
inflammation, proliferation and remodeling 4) A mature scar is produced that restores anatomical
and function to the wound.

These concepts apply to the problem of understanding and modeling the dynamics of a healing
wound detailed below. The wound healing system is composed of multiple levels of
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organizational scale including: multiple cell types (fibroblasts, neutrophils, macrophages, etc…),
intercellular messengers (cytokines, chemokines, hormones, growth factors, etc…), synthetic
products (collagen, proteoglycans, etc…), and enzymes (MMPs and TIMPs). The different cell
types produce and respond to the same cytokines in an autocrine and paracrine manner (multiple
pathways of interaction). As a result, a signal may be quickly amplified in the system or
dampened. The feedback loops that control the release and effects of the cell signals produce
nonlinear behavior. The behavior of the cells is determined not only by the current state of the
wound, but also the individual receptors that have been activated at earlier time points (statedependent and history-dependant behaviors). The normal process of wound healing contains
many separate but interacting events and host responses including microcirculatory oxygen
transport, immune and inflammatory responses, metabolic changes, and the neuroendocrine
system modulation. An unknown degree of these and secondary responses will occur due to
complex changes in genome expression. Instead of viewing each of these responses as separate
and independent mechanisms involved in the development of a healed wound it must be argued
that events leading to healing should be viewed through the complexity theoretic lens and that
wound healing is most effectively studied as a complex nonlinear system. Additionally, the
intracellular signaling pathways also consist of a complex system in itself (sub-system
hierarchies). Within each cell, there are multiple pathways that when activated by a receptor,
amplify a signal. Many times there are pathways that directly oppose each other that lead to
measured responses (multi-scale interaction). Cross talk and divergent pathways lead to many
complex relationships among the various signaling pathways. Therefore, a wound must be
considered a complex system composed of components that are themselves complex systems
(modular hierarchies of complex systems).
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Based on the previous discussion, it is clear that the study of the dynamics of wound healing
cannot be approached solely through traditional reductionist methodologies. We have
established that the experimental understanding currently demonstrates that wound healing is a
highly complex process that involves multiple cell types all of which are interacting in a
nonlinear fashion. These interactions take place over different time scales, across different
organismal hierarchies, and generate relationships through which unpredictable emergent
properties can occur[45,46]. For example, there are many feedback loops and redundancies in
the wound healing network (Figure 1) that make wound healing difficult to study. Feedback
loops give rise to the potential for oscillatory behavior, chaotic dynamics, and other nonlinear
phenomena. Topological structure of the network can give rise to unpredicted properties that are
defined, not by dynamical relations, but rather by spatio-structural ones[47,48]. Thus, it is not
sufficient to understand healing dynamics in terms of classical chemical reaction mechanisms;
rather, we must examine the integration of topological (spatio-structural and hierarchical) and
temporal (multi-scale) perspectives in order to truly understand the underlying mechanisms of
wound healing.

The previous description of complex nonlinear systems, as applied to wound healing, is highly
attractive in attempting to explain our failure in creating successful mono-target therapies. New
understandings tell us that the cells involved in wound healing and the cytokines and growth
factors used to transmit signals could be better categorized as highly complex, layered, modular
networks with stochastic dynamics at risk for dysfunction. The extent to which acute and chronic
soft tissue wounds can be modeled in terms of complex nonlinear systems, based on the
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Figure 1: Wound Healing Schema. The schema demonstrates the multiple feedback loops and
interactions among the components of the wound healing process.

preceding discussions and assumptions, is not at all clear. Examining the wound healing process
as a complex system may allow for discovery and for analysis of possible important emergent
properties of the system. These emergent properties, which again, can only be appreciated from
the whole of the interactions within the system, are what hold the potential promise of
breakthroughs in treatments and diagnostics.

Understanding that wound healing is most realistically represented through complexity theoretic
viewpoints now allows the traditional reductionist philosophy to be potentially complemented by
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the increasingly powerful new concepts of complexity theory. Effective studies of complex
systems must be made by analysis of the parts followed by a sophisticated reconstitution or
synthesis in order to model as much of the system as is known at the given time. The resulting
model must allow for almost an infinite number of input variables and provide a means to
interact with it. In essence, the resulting model is itself desired to exhibit its own emergent
properties allowing science to catch the necessary glimpses that provide for the creation of new
hypotheses. Manipulation of such a model will provide direction as to the subsequent approach
needed to take the next generation of steps in discovery.

An important concept while discussing normal wound healing is the concept of feedback and
feedforward loops. In order for wound healing to progress in a coordinated manner, each stage in
the healing process must not only self-perpetuate but also initiate the next stage. Furthermore,
each progressive stage must have the ability to turn off the previous stage once it has reached the
critical point at which it is no longer dependant on the previous stage for positive feedback to
continue. The interlocking feedback/feedforward loops allow for an orderly progression of
wound healing and prevents any one stage from inhibiting and/or preventing progress into the
next stage. The mechanism by which the different phases inhibit and promote each other is
through the expression of soluble mediators such as growth factors and cytokines. Each cell type
involved is capable of responding to and releasing a multitude of factors that allows the
formation of feedback/forward loops to control cell concentrations as well as activity.

In chronic wounds, failure of the normal wound healing process prevents normal wound closure.
There are multiple etiologies for the formation of chronic wounds that include diabetic ulcers,
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venous stasis ulcers, and pressure ulcers. Although ischemia is an underlying cause, each of
these wounds results from different pathological mechanisms; however all non-healing wounds
have remarkably similar wound healing trajectories as well as similar inflammatory profiles. In
the chronic wound, neutrophils are the predominant cell type with large amounts of proteases
and inflammatory cytokines. Because of the excessive amount of inflammation, it is likely that
these wounds have failed to progress from the predominantly inflammatory phase to a
predominantly proliferative phase. The wound is not able to mature, and the disorganized ECM
degrades liberating breakdown products, thus, causing further inflammation. As a result, the
chronic pressure ulcer becomes enmeshed in an inflammatory phase that self-perpetuates without
providing enough forward momentum to propel the process to the next stage of wound healing.
The effect of chronic inflammation is further tissue destruction and worsening of the chronic
wound thereby causing more inflammation and preventing any progress towards a healed wound.

Coagulation & Fibrinolysis- The coagulation and fibrinolytic (CF) systems comprise a series of
zymogen to enzyme conversions which ultimately terminate in the active proteolytic enzymes
thrombin and plasmin, respectively[49]. These enzymes catalyze the deposition and removal of
fibrin. When the system is functioning properly, blood is maintained in a fluid state yet rapidly
clots to seal endothelial injuries. A proper balance between the activities of the two cascades is
required both to protect the organism from excessive blood loss upon injury and to maintain
blood fluidity within the vascular system. Imbalance of the two cascades range from the full
spectrum of bleeding disorders (e.g. hemophilias) to thrombotic events (e.g. heart attacks and
strokes).
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In the event of injury to the endothelium, the CF system balances the need for localized clot
formation against the need to prevent system wide activation[50]. This finely tuned system is
composed of an assortment of molecular and cellular “agents” (e.g. substrates, enzymes,
cofactors, inhibitors, platelets, white blood cells and endothelial cells) which interact to generate
a stable clot in order to rapidly obtain hemostasis. The new cellular model of hemostasis
proposes that the classical pathways of coagulation, i.e., the intrinsic and extrinsic pathways,
mediate on specific cell surfaces in a tightly regulated manner. In this model, activation of factor
VII (extrinsic, Figure 2) and factor XII (intrinsic, Figure 2) result in the formation of multimolecular complexes, the tenase and prothrombinase complexes, which eventually generate
thrombin. Thrombin then cleaves fibrinogen to form fibrin monomers, which polymerize to form
a three-dimensional clot[51].

Clot formation is regulated in vivo primarily through the antithrombin III-heparin (AT-H),
activated protein C (aPC), and tissue factor pathway inhibitor (TFPI) pathways (Figure
2)[52,53,54]. These regulating systems limit the excessive formation of cross-linked fibrin under
hemostatic conditions thereby preventing thrombotic diseases.

The blood coagulation system is always active and primed for explosive generation of thrombin.
The positive feedback of the coagulation cascade in association with the negative feedback loops
of the three inhibitory systems (AT-H, aPC, and TFPI) imparts threshold properties to the
coagulation pathways[55,56,57]. As a result, there is a non-linear response to stimuli.
Furthermore, the presence of multiple coagulation inhibitors that act at different locations in the
cascade leads to a synergistic inhibition of explosive thrombin generation. Thus, there must be a
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Figure 2: Coagulation Cascade and Inhibitors- Inhibitors denoted by circles. The intrinsic
pathway is initiated by Prekallikrein or XII. The extrinsic pathway is initiated by TF. The
intrinsic and extrinsic pathway joins at the common pathway that begins after Factor X
activation. AT, TFPI, and aPC are the three inhibitory pathways.

significant pro-coagulant stimulus to overcome the inhibitory systems of coagulation. The
threshold effect and non-linear response of the coagulation system prevents activation when it is
not needed and localizes the response when it is needed.

The specificity of interactions, both molecular and cellular, involved in these complex processes
implies that systemic effects displayed by the CF system occurs through emergence of localized
events. The CF system may be viewed as a multi-component molecular machine, in which
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individual components are linked through multiple feedback and feedforward loops. This
introduces non-linear relationships among the components. A static diagram such as the
classically portrayed coagulation pathway (Figure 2) cannot adequately describe this dynamic
evolutionary network. Not surprisingly, the effects of several disease states on the imbalances in
the CF system are difficult to characterize utilizing the classic coagulation pathway. For
example, the influence of diseases that favor coagulation (e.g. coronary artery disease (CAD),
disseminated intravascular coagulation (DIC), cerebrovascular accidents (CVA), and deep
venous thrombosis (DVT)), or those that impair coagulation (e.g. hemophilias,
thrombocytopenias, and von Willebrand disease) remain poorly characterized in terms of the
interactions of all components in the system over time.

Coagulation is the first step in the repair of the damaged vessel[58]. Primary hemostasis is
defined by the formation of the hemostatic plug composed of platelets at the site of injury.
Secondary hemostasis is defined as the formation of fibrin strands by proteins in the blood
plasma, called coagulation factors that respond in a complex cascade which strengthen the
platelet plug. Secondary hemostasis occurs simultaneously with primary hemostasis. The
coagulation cascade is a network of biochemical pathways that perform the critical function of
preventing blood loss and repairing damage to the vasculature. The overall network is divided
into two major pathways: the intrinsic system and the extrinsic system. The intrinsic and
extrinsic systems converge to form a final common pathway . The common pathway leads to the
formation of α-thrombin. Thrombin serves to cleave fibrinogen to fibrin monomers. The fibrin
monomers then spontaneously polymerize to form a three-dimensional polymer = clot.
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The coagulation cascade is tightly regulated to limit the excessive formation of cross-linked
fibrin under hemostatic conditions and prevent spontaneous clot formation. The three systems
are the AT–heparin pathway, the tissue factor pathway inhibitor pathway , and the activated
protein C pathway (aPC).

Once the endothelial damage is repaired, the clot must be dissolved to allow wound healing to
progress normally. The fibrinolytic system operates to dissolve the pre-formed clot once the
underlying damage has been repaired (Figure 3)[59,60]. Fibrinolysis is achieved primarily
through the proteolytic action of plasmin on the fibrin polymers that reinforce and maintain the
integrity of a thrombus. Plasmin hydrolyzes the fibrin mesh at various places thereby making it
soluble. The dissolution of the fibrin clot produces circulating fragments that are cleared by
other proteases or by the kidney and liver. Similar to coagulation, the fibrinolytic system is
composed of interlocking positive and negative feedback loops.

Clot lysis is regulated in vivo primarily through the anti-plasmin (AP), plasminogen activation
inhibitor (PAI), and thrombin activatible fibrinolysis inhibitor (TAFI) pathways (Figure
3)[59,61,62,63,64,65,66]. Under normal conditions, these regulating systems delay the onset of
clot fibrinolysis until coagulation is complete.

The CF system has characteristics that make it difficult to study. The system is either at rest or
activated, i.e. nonstationarity. The system is not a homogenous chemical system (spatial
heterogeneity) in that clotting is localized at the site of endothelial injury. Lastly, the effects of
blood flow lead to continuous changes in coagulation factor concentrations and mechanical
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Figure 3: Fibrinolytic Cascade and Inhibitors- Inhibitors are denoted by circles. The
fibrinolytic pathway is initiated by tPA activation of Plasminogen. Plasmin hydrolyzes fibrin.
Plasmin and fibrin catalyze the conversion of Plasminogen to Plasmin

stresses on the clot. The complexity of the coagulation system has lead to difficulty in creating
therapeutic modalities. New pharmaceutical agents that modulate hemostasis have been
introduced into clinical practice such as recombinant factor VIIa and activated protein C. The
utility of these agents has been limited by the lack of measurement tools to characterize
coagulopathy . There is limited ability to determine: 1) indications 2) timing 3) dose of
administration. This has led to large scale, expensive but ultimately equivocal clinical trials.

In addition to the inherent characteristics of the CF systems that make it difficult to study, the
fact that the CF system is a complex system adds further difficulties. The CF system is
composed of a heterogenous collection of components including zymogens, enzymes, co-factors,
inhibitors, membrane surfaces and multiple cell types (endothelial cells, platelets, and white
blood cells). The CF system has no overlying controller and is composed of a series of local

27

biochemical reaction. The biochemical reactions that govern the system by their very nature are
non-linear. Lastly, threshold effects, localized clot formation, and time delayed fibrinolysis
emerge from the simple reactions of the heterogenous components.

One approach to approaching the study of the CF system is to integrate computational models
with the experimental data. The ideal computational model would allow the study of complex
diseases that involve coagulation such as DIC, trauma induced coagulopathy (TIC), cardiac
arrest, sepsis, DVT, MI, arterial thrombosis, genetic coagulopathy (hemophilia A/B, von
Willibrands disease, AT deficiency, factor V leiden, etc...), acquired coagulopathy (thrombotic
thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), idiopathic
thrombocytopenic purpura (ITP), thrombocytopenia, etc...). The model would find novel
mediators effecting coagulation, discover new therapeutic targets and treatment strategies.
Utilizing such as model would allow for testing over millions of iterations using the in silico
model. The outcomes associated with the model would include creation of bedside tools for realtime outcome determinations and dosing adjustments, enhance the probability for success once
the therapy is translated into the clinical setting, discover new mediators effecting coagulation
and interactions between systems including their proximal and distal effects, discover new
diagnostic and therapeutic targets that modulate the coagulation cascade to enhance outcomes,
create predictive tools for real-time outcome determinations of a patient‟s clinical state, create
real-time bedside tools to perform on-the-fly dosing adjustments for patients with simple or
complex coagulopathies or thrombotic disorders, and develop new software and algorithms for
simulation.
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Computational Biology
Due to the complex nature of biological systems, attempts to model them have concentrated on
simple, idealized versions. More recently, the traditional division of science into theory and
experiment has been complemented by computer simulation. A model is defined as a simplified
representation of a real system. Models are designed to: 1) describe phenomenon in such a
manner as to be comprehensible 2) make predictions. Models are used to explore general
mechanisms underlying complicated phenomena through: 1) examining (im)plausibility of a
proposed mechanism, 2) examining the effects of variations on simple models, and 3) acting as
virtual experiments to gain intuitive understanding of complex phenomena[3,67].

Fields such as mechanical engineering have successfully used computer models in the design of
tangible products such as automobiles and airplanes. When using computers to model complex
systems, they are used to model ideas. Simulations may be the only means available for
exploring complex systems when experiments are not feasible or they may be used to reduce the
time and cost performing “real” experiments. Such synthetic frameworks allow investigation of
systemic behaviors in biologic systems that are difficult if not impossible to study in vivo.

The idea that “All models are wrong, but some are useful" is critical for understanding the role of
computer simulations in the examination of complex systems. Models may lack universal
application, yet may still lead to new insights, new ways of examining phenomena, improved
models, and tools to build better models. A crucial component in the utilization of models is
understanding the limitation of the model, so that false conclusions are not derived from any
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results. The art of model building is the exclusion of irrelevant parts of the problem and correct
interpretation of the results.

Model building of complex systems poses unique challenges. As discussed earlier, a system is
defined as a collection of interacting elements that together produce, by virtue of their
interactions, some system wide behavior. In complex systems, the loss of emergent properties
that define the system prohibits an understanding of the system by studying the individual parts.
It is analogous to understanding the operation and construction of the space shuttle by reading its
parts inventory. Therefore, the system must be studied in a dynamic manner over time and
characterizing not just the components but also their relationships. For example, studying the
characteristics of isolated structures of a cell in isolation inadequately characterize the behavior
of the cell as a whole. Models based on computational systems biology attempt to integrate
experimental and computational research[68,69,70,71]. Ideally, computational systems biology
will provide tools to bridge the gap between traditional reductionist experiments,
genomics/proteomic data, and clinical care (translational medicine).

In this manner, technological and theoretical advances in computer science and mathematics
have offered new options to complement experimental study design. As opposed to in vivo
studies that are performed in living organisms and in vitro studies that are undertaken using cell
cultures, in silico studies utilize computational techniques[72,73,74]. The patterns discovered by
such techniques and the synthesis of experimental data and theoretical concepts allow creation of
models to explain complex phenomena. Effective studies of complex systems must be made by
analysis of the parts (the “omic” tree) followed by a non-linear recombination to model as much
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of the system as is known at the time[75,76]. In essence, the resulting model must exhibit its
own emergent properties, allowing science to catch necessary glimpses that provide for the
creation of new hypotheses. Manipulation of the model will then provide direction to the
subsequent methodologies necessary to take the next steps in discovery. The computational
challenge is creating models that contain sufficient elements and power to successfully predict
how the process will respond to interventions. To develop useful integrative systems biology
approaches, complexity theory and its computational tools must be utilized. This complexity
approach is consistent with the overall NIH Roadmap initiative and specifically with the
computational biology approach discussed in the initiative
(http://nihroadmap.nih.gov/bioinformatics).

Ideally, a well-constructed computational model will offer a virtual laboratory to test biological
hypotheses and therapeutic options prior to testing these theories in vitro or in vivo[77]. The
ability of any model, from cell cultures to in vivo animal models to mathematical models, to
make accurate predictions is dependent on the accuracy of the relation between the model and
the real-world process that is being modeled[78]. This is especially true of mathematical models
as all the observations are done in silico. Therefore, such a model will require extensive
validation in order to prove it is an accurate reflection of the biological process being modeled.

Validation of a mathematical model is focused at two points: the underlying assumptions and the
behavior of the model. The validation of the assumptions of the model can be addressed through
comparing the architecture and rules of the model with what is known about the components of
the modeled system. The difficulty lies in verifying the assumptions in the context of the in
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silico model as all models represent some degree of abstraction. Validation of the behavior of
the model consists of comparing the behavior of the model with some real-world data set of
expected behavior. When the behavior of the model matches the real-world process, then the
model is deemed valid for that particular test. I.E. the plausible validity of the model is based on
similarity to real world findings. Conversely, if the model behavior does not match, then the
model is invalid and must be reevaluated. Once the model is altered, the model must undergo
the validation process anew (Figure 4). One problem involves determining the next step when a
model behavior does not reflect real world behavior. The lack of fit may be due to calibration or
to an error in the basic structure of the model; this validation will require extensive literature
searches to obtain additional mechanistic insight as well as trial and error attempts at
reconstruction.

The advantages of developing a successful mathematical/computational model cannot be
overstated. Scientist will be able to test hypothesis nearly instantaneously. A successful model
will target promising novel therapeutic approaches, thereby improving the success rates of
clinical studies. It will also promote the discovery of new therapeutic approaches that come
directly out of the modeling process. The time from bench to bedside will be decreased as
millions of experiments may be run on a model in a very short period of time allowing the
investigator to choose the best possible intervention strategy prior to any clinical trial[79].
Intervention strategies may be streamlined and personalized prior to clinical application.

Ordinary differential equations- ODEs provide a valuable tool for analysis and prediction of
biological systems over time. The ODE paradigm is based on a series of equations that describe
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Figure 4: Computational Modeling Flow Diagram. The flow diagram demonstrates the
iterative process required for creation of a high performance, validated model.

the change in the states of the variables of the system over time[80]. The differential equations
are derived from a combination of known and hypothesized kinetics of the components of the
biologic system[81,82]. In general, the equation variables represent average concentrations of
the various components. Furthermore, parameters are embedded in the equations that represent
the state of the system being modeled. If they are not too complex, a system of ODEs can be
solved analytically. Otherwise, they can be solved computationally and analyzed using methods
from nonlinear analysis to explore the properties of the system. Because these equations are
based on biologic interactions, ODE can predict outcomes beyond the range of available data.
The most valuable aspect of an ODE is the ability to manipulate the variables allowing the
manipulation of a biologic mechanism and providing an outcome that may be analyzed; thereby,
allowing in silico experiments and subsequent in vivo experimental validation.
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Such a dynamic systems can used to capture the gross behavior of the system. The advantages of
using ODE include: 1) the ability to explore properties of the system using non-linear analysis
techniques 2) prediction of outcomes beyond the range of available data, and 3) manipulation of
variables to determine the effects on the system. Unfortunately, there are also disadvantages of
ODE including: 1) multiple feedback loops lead to equations that are difficult to solve, 2) a
priori necessity of a complete description of the system, and 3) spatial dynamics are difficult to
simulate.

Agent Based Modeling - In order to address the shortcomings associated with ODE models, we
present the application of a computational systems biology approach using agent based modeling
and simulation (ABMS)[83,84]. ABMS provides a powerful alternative to differential equations.
ABMS is a relatively new modeling paradigm derived from cellular automata (CA). CA was
originally developed by Stanislaw Ulam and John von Neumann and more recently popularized
by Stephan Wolfram[85,86,87]. CA is an abstract mathematical representation of a machine,
which can be made to operate on a set of rules. A CA is a 2-D grid consisting of spaces called
“cells”. Each cell is allowed to assume a finite number of states, each of which is determined by
a pre-defined set of update rules. A CA update rule is defined as the rule that every CA follows
that determines its state at the next time step as a function of its current state and the state of its
neighbors. Thus, CA are complex systems in that you have large numbers of components with
no central controller and only local communication. Such CA may exhibit emergent behaviors
that cannot be predicted from the CA rule. ABMS is an extension of CA in that it has mobile
components that can move through the grid.
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ABMs analyze biological systems based on the interactions among its components. ABMs are
dynamic systems that are discretized: time, space, and internal state[3,88,89,90]. ABM behavior
is defined by rules that are a function of their local environment and their state. ABM models
are built on a grid of usually square spaces that are capable of entering a finite number of states.
Each agent is assigned a state with a discrete probability of interacting with agents around it.
Every agent has the same set of rules for updating its internal state. Based on the values of its
neighboring agents and its current state. At each time step, the rules are applied to the whole
grid and a new generation of agents is created

ABMs are based on creating rules and defining mechanisms of behavior for the individual
components of system. The components of a system are classified into types of agents by virtue
of shared behavior. The behavior mechanisms are expressed as a series of conditional rules that
allow easy conversion into computer programs. Again the rules are created based on known and
hypothesized mechanisms. A simple example would be the creation of an agent that represents
fibroblasts that when exposed to TGF-B synthesizes collagen. The model defines a world based
on defined characteristics and generates populations of the various types of agents. The agents
are able to interact based on programmed behaviors that are defined by their rule systems
initiated by inputs from their environment. For example, fibroblasts would respond to growth
factors and cytokines that are secreted by other fibroblasts that they encounter in their immediate
neighborhood. In order to mimic real systems, the agents run in a parallel. The resulting
dynamics of the system then emerge from the multiple interactions between the agents over time
rather than dictated by an overlying controller. This type of modeling is “bottom up,” as all
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measured output parameters and the resultant outcomes from the model are generated by the
actions of the individual agents. One of the advantages of ABM is the intuitive rule based
definitions that are easily understood by non-mathematicians. Furthermore the mechanistic rule
based nature of ABMs allows the simulation of any intervention that deals with a defined
mechanism.

Agent based modeling is an approach to simulating the behavior of a complex system in which
agents interact with each other and with their environment through simple local rules. Again the
rules will be derived from experimental data as well as literature-mining. The advantage of such
a technique include: 1) non linear relationships are easily modeled 2) the model is intuitive and
does not require higher level mathematics for use and understanding, and 3) flexibility. The
disadvantages of agent based modeling include: 1) difficulty with validation 2) large amounts of
computational power needed for large simulations.

ABMS provide significant advantages over other modeling paradigms when modeling biologic
systems[79,83,84]. The models are flexible in that changes in agent behavior may be done
without having to reprogram the whole model. This flexibility allows a wide range of behaviors
to be captured. The coding of such models may be mechanistic based. Every aspect of how
agents behave and interact must be explicitly coded. Additionally, the variables that determine
the agents‟ behavior must also be defined. This behavior is usually coded at mechanistic levels
allowing hypothesis to be easily tested. The agents are able to adapt and change their behavior
based on their environment. As all biological processes are inherently dynamic, the ability of
such agents to capture the dynamic behavior of systems is critical. The models are easily
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scalable. Once the behavior of a given agent is defined, inhabiting a system with multiple
instances is easy. Therefore, examining the behavior of a system of arbitrary size is more a
function of computational speed and systems resources rather than ability to generate larger
models. One of the greatest strengths of such models is to create virtual experiments. The
experiments can be repeated an arbitrary number of times and the data can be analyzed using
traditional statistics. This allows direct comparisons between the in silico models and in
vivo/vitro experimental data. ABMS allow constructive proofs of systems. I.E. you create a
model that generates a behavior. Regardless of in vitro/vivo observation of this behavior, the in
silico model results imply that there is at least one set of conditions that may create such
behaviors. This allows us to grow generative models that capture systems as they are expanded.
Another important aspect of such models is their ability to run many experiments at a very low
cost. Once the model is created, the cost of running such models is usually minimal.
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Abstract

The complex interactions that characterize acute wound healing have stymied the development
of effective therapeutic modalities. The use of computational models holds the promise to
improve our basic approach to understanding the process. By modifying an existing ordinary
differential equation model of systemic inflammation to simulate local wound healing, we expect
to improve the understanding of the underlying complexities of wound healing and thus allow for
the development of novel, targeted therapeutic strategies. The modifications in this local acute
wound healing model include: evolution from a systemic model to a local model, the
incorporation of fibroblast activity, and the effects of tissue oxygenation. Using these
modifications we are able to simulate impaired wound healing in hypoxic wounds with varying
levels of contamination. Possible therapeutic targets, such as fibroblast death rate and rate of
fibroblast recruitment, have been identified by computational analysis. This model is a step
towards constructing an integrative systems biology model of human wound healing.
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Introduction
A soft tissue injury elicits a well-prescribed wound healing response1, 2. The process of wound
healing is designed to restore anatomic and functional characteristics of the tissue; however, little
progress has been made in improving the wound healing response time or in preventing
complications such as fibrosis, infections, and formation of non-healing wounds3. In this paper,
we describe a computational model of acute wound healing designed to allow a system-level
analysis of the wound healing response using ordinary differential equations (ODEs). As a first
step to a more comprehensive model, we have explored the combined effects of bacterial
infections, inflammation, and tissue hypoxia on the rate and success of wound healing since
these processes are well-known as affecters of healing. As this model matures, it will provide
the opportunity to test new mechanisms and novel therapeutic of wound healing strategies in
silico.

Despite burgeoning interest in the field of computational biology, work of limited scope has been
published on modeling the acute wound. Most of these studies demonstrate the difficulties of
adequately accounting for the myriad of potential interactions9. For example, in their respective
works on epidermal wound healing, Stekel et al.10, Walker et al.11 and Morel et al.12 do not
attempt to simulate healing by fibroblasts and do not implement inflammatory changes in their
models. Dallon et al.13 constructed an ODE model of collagen deposition focusing on the
fibroblasts and their relationship to the underlying extracellular matrix, but do not account for
inflammation or repair of underlying tissue damage. Schugart et al.14 recently published a model
of wound angiogenesis as a function of tissue oxygen tension but the model does not specifically
address the wound healing process.
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Reynolds et al.15-16 created an ODE model designed to simulate inflammation and repair on a
systemic level in the setting of a systemic insult such as sepsis. We have modified and extended
their work to apply it to a local wound. ODEs provide a valuable tool for analysis and prediction
of biological systems over time17. ODEs model the changes in important physiological variables
over time. The equations are derived from a combination of known and hypothesized kinetics of
the components of the biological system. In our model, the state variables represent average
concentrations of the various dynamic components. Furthermore, parameters are used in the
equations to account for static components of the system being modeled. The system is solved
numerically and the properties of the system can be explored mathematically. Because these
equations are based on biological interactions, ODEs can predict outcomes beyond the range of
available data. The most valuable aspect of a mathematical model is the ability to manipulate the
variables and parameters, perform experiments in silico, and examine their results. The
biological mechanisms of a wide range of potential situations may then be analyzed together
with their outcomes. In vivo validation would then follow from in silico experimentation.

Materials and Methods
As a first attempt to capture the dynamics of local wound healing over time, a four-variable
system of ordinary differential equations was developed. The variables in this model represent
total local tissue (D)amage, (P)athogen level, overall i(N)flammation, and the concentration of
(F)ibroblasts. For each of these variables we used known biological interactions to develop a
differential equation that describes the rate of change for the variable. The interactions included
in this model are depicted in the model schematic, Figure 1.

41

Figure 1: Model schema that illustrates the interactions between the four variables. Arrows indicate positive
feedback and bars indicate negative feedback.

The fundamentals of the model are based on the observations that tissue damage is increased by
inflammation and hypoxia, while wounds are repaired by fibroblasts18-21. Interpreting the
interactions in Figure 1, we developed the four variable model, given below in Equations (1)-(4).
This model was adapted from the four variable model created by Reynolds et al., which is
included in Appendix A.
k pmsm P

dP
P
 pgrowth P  1  
 k pn f (N; F)P
dt
P  m  kmp P


(1)

s R(P, N , D; F)
dN
 nr
  fn FN  n N
dt nr  R(P, N , D; F)

(2)

 D2 
dD
 kdn fs ( f (N; F))  d D  df DF  d g(O2 )  2
2
dt
 D  xd 

(3)
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The difficulties in modeling complex physiologic processes are defining the system variables and
representing their interactions mathematically. To address this, we have combined related cell
types and signaling process together. As a result, it is not possible to have units on many of the
biological quantities. Specifically, because tissue damage is complex and involves many
biological markers, it is a difficult quantity to measure. Thus in this model D has no units.
Instead, we track the relative changes over time and evaluate healing based on percentage change
of damage (D), with a return to under 10% damage considered healed.

Pathogen Equation
In developing Equation (1), the pathogen equation, we made similar assumptions to those used to
develop the pathogen equation in Reynolds et al. We assumed that the pathogen population has
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a growth rate of pgrowth and a carrying capacity of P∞ giving rise to the first term of Equation.
Unlike the Reynolds et al. model we take into account that the pathogen population is increased
in low oxygen environments19. Therefore, pgrowth is a function of the oxygen level in the local
environment and determined by the function:

This relationship between tissue oxygenation levels and bacterial growth is illustrated in Figure
2a. with Ocrit set to 5, which is equivalent to a transcutaneous oxygen level of 30mm Hg22, 23. If
the tissue oxygen level is above the critical value, pgrowth is fixed at 0.3, since the effects of
hyperbaric oxygen on wound healing are not included in this model. However, this function
does capture the increase in anaerobic pathogen reproduction that occurs in hypoxic
environments. The second term in Equation (1) is directly from the Reynolds et al. model and
accounts for local immune mediators that immediately interact with the pathogen, such as
defensins and non-speciﬁc antibodies.

Inflammation recruited to the wound is generally thought to assist in the destruction of pathogens
and thereby is assumed to decrease pathogen levels, while causing some degree of tissue
damage2, 4, 24-26. The effect of this process on pathogen level is modeled with the third term of
Equation (1). We model the depletion of pathogen from an encounter with an inflammatory cell
with a term of the form k pn N P . However, since fibroblasts modulate the inflammatory
response by initiating wound repair, N in this term is replaced with f (N; F) .
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Figure 2: (a) Dependence of the pathogen growth rate on tissue oxygenation. Anaerobic pathogen growth rate
increases at lower oxygen levels. (b) Graph of the function g(O 2), illustrating the impact of tissue oxygenation on
rate of damage increase. Oxygen levels below the critical level Ocrit promote additional damage, whereas higher
oxygen levels decrease the rate of damage.

The function f (N; F) represents the inhibition of inflammatory cells by fibroblasts. We use the
same definition of the function f (N; F) as in Reynolds et al., since we are modeling the downregulation of the same cell population. Including this inhibition produces the third term of
Equation (1): -kpnf(N; F)P.

Inflammation Equation
Inflammatory cells are recruited by pathogens, damaged tissue, and other inflammatory cells and
mediators21, 25. Incorporating this activation of the inflammatory cells into the model we get the
first term of inflammation equation, Equation (2). First we assume that inflammatory cell
activation is triggered by the three variables N, D, and P giving a rate of activation of

R  knp P  knn N  knd D. As in the pathogen equation, Equation (1), we account for the inhibition
of inflammation due to the presences of fibroblasts and we replace the basic activation rate with
one that includes inhibition R(P, N, D; F)  f (knp P  knn N  knd D; F) . The process of activation
occurs on a faster time scale than the other interactions included in this model, this allows us to
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not explicitly track the resting population of inflammatory cells, and to model activation with the
sigmoid function

snr R(P, N , D; F )

nr  R(P, N , D; F )

. Further details on the derivation of this term are in

Reynolds et al.

Fibroblasts are recruited to the wound by tissue damage and inflammation and are able to repair
tissue damage and modulate the inflammatory response 2, 4, 27-29. This modulation of the
inflammatory response is represented with the term   fn FN in Equation (2). The inflammation
population will decrease at greater rate when fibroblasts are at a higher level.
The majority of cell types, such as inflammatory cells and fibroblasts, are not immortal; their
half-life determines the duration of their efficacy30, 31. Therefore, as traditionally found in most
ODE models, the half-lives of inflammatory cells and fibroblasts were used to represent the
average decay rate of a cell17. Incorporating the intrinsic decay of the inflammatory cells we get
the final term of Equation (2),  n N .

Damage Equation
Tissue is damaged not only by the initial wound, but also by the influx of inflammatory cells to
the wound site during the inflammatory stage of wound healing. To model this dependence of the
damage level on the inflammation we use kdn f s ( N ) . The function fs is a nonlinear function of N,
because low levels of inflammation are not as effective at inducing tissue damage. We also
include inhibition of inflammatory cells in this term. Therefore, in Equation (3), we have the
term kdn f s ( f ( N ; F )) .
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The amount of damage that is repaired is proportional to both the current amount of damage and
the amount of fibroblasts present. This leads to the term df DF in the damage equation,
Equation (3). Damage is decreased at a faster rate when fibroblast levels are higher. Also we
include the term d D in Equation (3) to model intrinsic tissue repair.

The final term in Equation (3) models the impact of tissue oxygenation O2 level on the rate of
change of damage. This impact is described by the function g(O2) (Figure 2b), which is designed
to capture the increase in damage in hypoxic environments and to represent a small healing
effect if O2 is larger than the critical value, Ocrit22. 23.

Fibroblast Equation
The final equation, Equation (4), models the fibroblast population. We assume in normal skin
there is a background source of fibroblasts, sf. This gives rise to a baseline level of circulating
fibroblasts, which exist in both pre-wounded tissue and healed tissue.
In response to tissue damage and inflammation, the fibroblast population will increase. The
second term in Equation (4) models this growth when inflammation and/or damage are nonzero.
The term has the form

k fn ( N  k fnd D)
1  ( N  k fnd D)

because we assume the dependence of the fibroblast

population on levels of damage and inflammation is nonlinear. That is, at low levels of
inflammation and damage the recruitment of fibroblast is slow, while at high levels the process
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of fibroblast recruitment saturates. As with other terms involving inflammation the process is
inhibited using the same function, f, so the final form of the term is
As described above, fibroblast have an intrinsic death rate

f,

k fn f ( N  k fnd D; F )
1  f ( N  k fnd D; F )

.

and this is modeled by the final

term of Equation (4),   f F .

Simulations
Our model equations were solved numerically using both the software package XPPAUT32
(XPPAUT is a freely available software package for solving differential equations available for
download at http://www.math.pitt.edu/~bard/xpp/xpp.html) and several of our own
independently developed C++ computer programs. A list of baseline parameters is included in
Table 1 for reference. The parameters were derived from experimental values found in the
literature or estimated such that the system behaved in a biologically appropriate manner15, 22, 23.
We performed several in silico experiments to investigate the effects of (i) varying the amount of
initial damage, D(0), and the initial pathogen levels, P(0), and (ii) varying certain parameters
such as the tissue oxygenation level O2 and the rate of fibroblast recruitment sf.

In each experiment, we simulated two weeks of the wound healing process (336 hours) after the
initial wound insult in order to observe more of the transient effects en route to steady state33.
Two weeks provides an adequate amount of time for normal wounds to heal. The resulting end
state of the wound was categorized as one of three types:


Healed if the damage is decreased by 90% within 2 weeks (i.e. for D(0)=10, damage is
less than 1 after 2 weeks);
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Non-healing wound if damage remains higher than 10% of initial damage and pathogen
levels decrease to zero (i.e. for D(0)=10, P(0)>0, damage is greater than 1 but pathogens
are nonexistent after 2 weeks); and



Chronic infection if both damage and pathogen levels remain at above 10% of their initial
levels after 2 weeks (i.e. for D(0) =10, P(0) = 1, damage is greater than 1 and pathogen is
greater than 0.1 after 2 weeks).

The non-healing wounds as defined above correlate clinically to wounds in which there is
impaired wound healing, but are not infected2-4, 24, 34, 35. Chronic infections as defined above
correlate clinically to wounds that are infected and are thereby unable to heal normally2-4, 34, 35.

Results
All simulations started immediately after the wound formation. In the model, this translated to
no initial inflammation (N(0)=0) and to the initial level of fibroblasts at a normal background
level (F(0)=0.1). Initial damage and initial pathogen levels were set to represent different injury
scenarios. Unless otherwise specified, all parameter values were set to their baseline values
(Table 1).

Figure 3 is the baseline simulation and shows normal healing behavior in a small,
uncontaminated wound with normal perfusion (D(0) =0.2 and P(0) = 0). As expected, this type
of wound elicits a brief period of a slightly elevated inflammatory response and an increase in
fibroblast level. This scenario results in normal healing of the wound, which is represented by
the damage variable decreases to zero within two weeks.
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Figure 3: Healing behavior of a small, “clean” wound (D(0) = 0.2, N(0) = 0, F(0) = 0.1, and P(0) = 0). (b)
Inflammation peaks within two days after initial insult, and decays to 0 within two weeks. (c) Damage steadily
decreases, and after two days the amount of wound damage is approximately half its initial amount. (d) Fibroblasts
peak three to four days after initial insult, and then return to their baseline value within two weeks.

The first experiment focused on increasing the initial wound size (D(0) = 2; 10-fold increase
from Figure 3) while leaving pathogen levels at zero (P(0) = 0). Figure 4 illustrates the effect of
this change on the behavior of the wound. The significantly increased initial wound size, leads
to a non-healed wound at two weeks where damage, fibroblasts, and inflammation all plateau at
an elevated level. This correlates clinically to large acute wounds that require prolonged healing
times and are at increased risk for developing infections4, 36.
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Figure 4: Non-healing wound of large initial size and no initial pathogens (D(0) = 2, N(0) = 0, F(0) = 0.1, and P(0)
= 0). (a) The pathogen level remains at 0 for the duration of the simulation. (b-d) Inflammation, damage, and
fibroblast levels plateau at elevated levels, and the wound persists even after two weeks.

Figure 5 shows the impact of tissue oxygenation levels on wound healing behavior by plotting
the pathogen and damage levels for three different levels of O2. For each level of oxygenation
the wound has a moderate initial size and pathogen level (D(0) = 0.5 and P(0) = 0.3). All
parameters except O2 were held at their baseline values. If the tissue oxygenation is at the
borderline level (O2 = O2crit=5.0; equivalent to a transcutaneous oxygen level of 30mm Hg22, 23),
the wound begins to heal after a two-day transient period during which the amount of tissue
damage increases in size as a result of the inflammatory response (Figure 5 a,b).
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Figure 5: Transients for pathogen and damage with various O2 values. For all three O2 values the initial conditions
used were D(0) = 0.5, N(0) = 0, F(0) = 0.1, and P(0) = 0.3. (a) and (b): are the pathogen and damage transients,
respectively, for a O2 value of 5, which is the value of O2crit. (c) and (d): the pathogen and damage transients,
respectively, for a O2 value of 4.0, which results in a non-healing wound. (e) and (f) : the pathogen and damage
transients, respectively, for a O2 value of 2.5, which results in a chronic infection.

Both the damage and inflammation return to zero and the fibroblasts are decreasing toward their
background level by the end of two weeks. We also simulated the same wound in a reduced
oxygen environment, where O2 is below the critical level (O2 = 4.0), which leads to significant
impairment in wound healing (Figure 5 c,d). The pathogens are successfully removed, but
damage persists beyond two weeks. Finally, if the tissue oxygenation is further lowered (O2 =
2.5), both pathogens and damage plateau at an elevated level, corresponding to chronic infection
(Figure 5 e,f). These represent the types of non-healing wounds, both infected and non-infected,
seen in patients with vascular insufficiency2, 37.
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In a third experiment, we investigated the combined effect of tissue oxygenation (O2) and
f

) on the wound healing behavior, leaving all other parameters at their

baseline values. By increasing the fibroblast mortality rate, we simulated the premature
senescence of fibroblasts observed in older patients and diseases such as diabetes mellitus4, 36, 38.
Figure 6 illustrates the wound healing behavior for different choices of initial conditions. In
Figure 6a, the initial damage and pathogen levels are low (D(0) = 0.2 and P(0) = 0.2), and the
wound always heals within two weeks if O2 > Ocrit
0.01). If the

f

f

=

> 0.14), the high mortality of

fibroblasts invariably results in a non-healing wound. In hypoxic environments, we observe nonhealing wounds even when fibroblast mortality is low as a direct result from tissue necrosis.
Figure 6b shows the impact of doubling the initial pathogen level (P(0) =0.4). In this case, both
the regions of non-healing wound and chronic infection become substantially larger.

Figure 6: Long-term wound behavior for various choices of tissue oxygenation O 2 and fibroblast mortality (μf) (
N(0) = 0 and F(0) = 0.1). (a) A wound with initial damage D(0) = 0.2 and pathogen level P(0) = 0.2. Large
fibroblast mortality always leads to non-healing wound. If the fibroblast mortality is lower, then we observe chronic
infection in hypoxic environments and healing if tissue oxygenation is appropriately large. (b) If the initial pathogen
level is doubled to P(0) = 0.4, the regions of chronic infection and non-healing wound are substantially larger, and
the wound is unable to heal within 2 weeks time. Simulations were not run for fibroblast half-life values less than 12
hours (marked by the dashed lines in each plot), since values below this level are typically unseen.

To understand if an advanced therapy might impact wound outcome, we designed an in silico
experiment to investigate the possible impact by varying the rate of fibroblast recruitment (sf),
and analyzed the long-term healing behavior. We simulated the first two weeks after initial
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insult for a wound with baseline initial conditions D(0) = 0.5, N(0) = 0, F(0) = 0.1, and P(0) = 0,
for all parameters except fibroblast recruitment (sf). For larger recruitment rates (sf > 0.012), the
wound heals within two weeks, whereas a non-healing wound results if recruitment is impaired
(sf < 0.011). Increasing sf, i.e. recruiting more fibroblasts, has a strong impact on the overall
healing time. For example, if sf = 0.001, the wound requires 158.2 hours to shrink to 10% of its
original size, as compared to 139.0 hours if sf is doubled to 0.002 (Figure 7).

Figure 7: Comparison of damage vs. time for different fibroblast recruitment rates (D(0) = 0.5, N(0) = 0, F(0) =
0.1, and P(0) = 0). The dashed curve is damage transient for the baseline fibroblast recruitment rate, s f = 0.001. The
solid curve is the damage transient with the same initial conditions and a fibroblast recruitment rate twice baseline, s f
= 0.002.

By doubling sf, the healing time decreases by about 12%. The maximum amount of damage,
which accumulated as the wound healed, decreased by 11%. Furthermore, when sf=0.002 the
influx of inflammation to the wound site did not elicit more damage than the initial level of
D=0.5. These experiments correlate to the use of agents such as recombinant PDGF39 and basic
fibroblast growth factor, bFGF40. The Akita et al.40 study reported a 20% decrease in healing
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time with the use of bFGF, which is on the same order of magnitude as the decrease seen our
model experiment.

Discussion:
Mathematical models offer a non-invasive intermediary step between animal models and human
subject studies that allows hypotheses and therapies to be tested prior to clinical studies. An in
silico model would potentially increase the success rate of clinical trials or aid in designing more
appropriate animal studies. These animal or clinical studies would then in turn, validate the
model.

As an initial step to creating such a model, we have modified an ODE model of the acute wound
healing response to a soft tissue injury. The model includes factors such as bacterial
contamination and wound oxygenation. Assuming normal conditions, our model predicts the
typical progression of healing behavior for a wound. The ODE model was also able to
successfully simulate the impairment in wound healing found in a hypoxic wound environment
and a contaminated wound. With extremely low levels of oxygen, our model predicts a chronic
infection where the wound does not heal and pathogens persist in the wound. Both of these
states are well documented clinically35, 38.

We also examined the situation of elevated and depressed fibroblasts mortality rates. Clinically,
instances of elevated fibroblast mortality are seen in diabetic and elderly patients. Here we saw
that with high rates of fibroblast mortality the wound cannot heal. Additionally, a scenario of
moderately low fibroblast mortality and high initial pathogen levels predicts the state of chronic
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infection. Finally, we examined the case where fibroblast production is either impaired or
enhanced. Impaired fibroblast production results in a non-healing state, but under conditions
where the production is increased we have wounds that heal at notably faster rates. This
provides a framework from which to test a new hypothesis in a living model.

The present study represents only a first step toward developing a detailed mathematical model
of acute wound healing. Consequently, there are many opportunities for improving upon our
existing model; these include,


With the exception of time t, all quantities are measured in arbitrary units. By expanding
the model to include variables that represent specific cell types and mediators one may
estimate parameter values and assign physiologically meaningful units.



In its present form, our model does not incorporate time delays. This prevents the
simulation of the time lags inherent in signaling pathways as well as in fibroblast
recruitment after the onset of inflammation.



We did not attempt an exhaustive study of the impact of individual parameters on longterm healing behavior. Although we chose to focus on parameters such as the production
and death rates of fibroblasts, it is likely that other parameters have a profound impact on
healing.



We focused on strongly interlinked local factors (inflammation, fibroblast function and
recruitment, bacterial contamination, and tissue oxygenation) with resultant dynamic
non-linear behaviors. Factors such as depth and shape of the wound, wound contraction,
epithelization, and angiogenesis have not been addressed.
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We have not included systemic effects on wound healing, e.g., nutritional status, age, sex,
and underlying comorbidities.

Despite the limitations inherent in our model, it does demonstrate the to use a systems biology
approach to human wound healing. Mathematical models show great potential as a platform for
hypothesis generation and experimentation prior to further refinement in vitro and in vivo. A
refined method of computational analysis would decrease overall cost, time, and need for
invasive testing. In the future, we hope to further elucidate the process of inflammation,
epithelization, contraction, angiogenesis, and systemic effects, in order to create a model that
more closely corresponds to the actual wound environment. Because our simplified model
produces qualitatively reasonable results, we are optimistic that including systemic effects will
enhance our understanding of the acute wound-healing process, ultimately leading to improved
clinical therapies.
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Table 1. Baseline parameter values. * denotes estimated parameter
Parameter
Value
Comments
kpm

0.6

Rate at which inflammatory cells kill pathogen
nonspecifically*.

kpn

0.6

Rate at which inflammatory cells kill pathogen by
phagocytosis15.

µn

0.05

Half-life of activated inflammatory cells15.

F∞

0.30

Maximum fibroblast density*.

kmp

0.01

Rate at which non-specific inflammatory response is
exhausted by pathogens*.

knp

0.1

Rate of activation of inflammatory cells by pathogens*.

knd

0.015

Rate of activation of inflammatory cells by damaged tissue*.

sf

0.001

Rate of fibroblast recruitment*.

sm

0.005

Rate of inflammatory cell recruitment*.

knn

0.01

Rate of activation of inflammatory cells by activated
inflammatory cells*.

kdn

0.35

Maximum rate of damage by activated inflammatory cells*.

kfn

0.004

Rate of fibroblast recruitment by inflammatory cells*.

kpg

0.55

Rate of pathogen growth15.

snr

0.08

Rate of inflammatory cell recruitment*.

xdn

0.1

Level of inflammatory cells needed to bring damage to half
its maximum*.

kfnd

48

Effectiveness of tissue damage and inflammatory cells to
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recruit fibroblasts15.
P∞

20

Maximum pathogen density15.

µnr

0.12

Half-life of inactivated inflammatory cells15.

µd

0.02

Baseline damage repair rate15.

µf

0.01

Half-life of the fibroblasts*.

µm

0.002

Half-life of non specific inflammation15.

µdf

0.002

Determines the amount of damage healed per unit damage
per fibroblast*.

µfn

0.002

Determines that anti-inflammatory effects of fibroblasts*.

α

0.1

Along with µd, determines the amount of damage inflicted
by hypoxia*.

xd

2

Along with βd determines the rate of tissue damage caused
by hypoxia*.

βp

0.3

Along with O2/ Ocrit ratio, determines the increase in
anaerobic reproduction rate induced by hypoxic conditions*.

βd

0.3

Determines the rate of tissue damage caused by hypoxia*.

Ocrit

5

Critical oxygen level below which wound healing is
impaired. Equivalent to a transcutaneous oxygen level of
30mm Hg22, 23.

O2

User
Defined

*Estimated parameter

Level of tissue oxygenation.
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Appendix A

The original equations from Reynolds et al.15 are:


dP
P k s P
 k pg P 1    pm m
 k pn f ( N * ) P
dt
 P  m  kmp P
s R
dN *
 nr
 n N *
dt
nr  R
dD
 kdn f s ( f ( N * ))  d D
dt

k f ( N *  kcnd D)
dC A
 sc  cn
 c C A
dt
1  f ( N *  kcnd D)
R  f (knp P  knn N  knd D)

f (V , C A ) 

V
1  (C A / C A )2

CA represents the amount of system anti-inflammatory mediator. The parameters sc, kcn and kcnd
correspond to Sf, Kfn, and Kfnd, respectively. N* represents inflammation and all other variables
and parameters are represented by the same notation as used in our model.
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Abstract:
The coagulation and fibrinolytic systems are complex, inter-connected biological
systems with major physiological roles. The complex, nonlinear multi-point relationships
between the molecular and cellular constituents of two systems render a
comprehensive and simultaneous study of the system at the microscopic and
macroscopic level a significant challenge. We present an Agent Based Modeling and
Simulation (ABMS) approach for simulating these complex interactions. Our ABMS
approach utilizes a set of 106 rules to define the interactions among the 59 enzymes
and factors of the coagulation/fibrinolysis (CF) system interacting with each other in a
dynamic manner. These rules simulate the interaction of each “agent”, such as
substrates, enzymes, and cofactors, on a two-dimensional grid. This ABMS method
successfully reproduces the initiation, propagation, and termination of blood clot
formation and its lysis in vitro due to the activation of either the intrinsic or extrinsic
pathways. Furthermore, the ABMS was able to simulate the pharmacological effects of
two clinically used anticoagulants, warfarin and heparin, as well as the physiological
effect of an enzyme deficiency/dysfunction, i.e., hemophilia and antithrombin III-heparin
binding impairment, on the coagulation system. The results of the model compare
favorably with in vitro experimental data under both physiologic and pathophysiologic
conditions which assist in substantiating the model.

Introduction:
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The coagulation and fibrinolytic systems maintain a constant, delicate balance between
thrombotic response to acute blood loss versus the requirement of the vascular system
to allow constant blood flow. Zymogen to enzyme conversions throughout these two
cascades generates the proteolytic enzymes, thrombin and fibrin, that catalyzes the
deposition and removal of fibrin respectively. Disruption of this equilibrium results in
thrombotic events (e.g. pulmonary embolus) versus hemorrhagic events stemming from
underlying coagulopathies (e.g. vonWillebrand's disease)1

In the event of an injury to the endothelium, the coagulation system balances the need
for localized clot formation against the need to prevent system wide activation. This
finely tuned system is composed of an assortment of molecular and cellular “agents”
(e.g. substrates, enzymes, cofactors, inhibitors, platelets, and endothelial cells which
interact to generate a stable clot in order to rapidly obtain hemostasis. The new cellular
model of hemostasis proposes that the classical pathways of coagulation, i.e., the
intrinsic and extrinsic pathways, mediate on specific cell surfaces in a tightly regulated
manner. In this model, activation of factor VII (extrinsic, Fig. 1) and factor XII (intrinsic,
Fig. 1) result in the formation of multi-molecular complexes, the tenase and
prothrombinase complexes, which eventually generate thrombin. Thrombin then cleaves
fibrinogen to form fibrin monomers, which polymerize to form a three-dimensional clot.
Following repair of the underlying damage to the endothelium, the fibrinolytic system
acts to dissolve the pre-formed clot. Fibrinolysis is achieved primarily through the
proteolytic action of plasmin on fibrin polymers that reinforce and maintain the integrity
of a thrombus (Fig 2).
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Figure 1: Coagulation Cascade and Inhibitors- Inhibitors denoted by circles. The intrinsic pathway is initiated by
Prekallikrein or XII. The extrinsic pathway is initiated by TF. The intrinsic and extrinsic pathways join at the
common pathway that begins after Factor X activation. AT, TFPI, and aPC are the three inhibitory pathways.

Clot formation is regulated in vivo primarily through the antithrombin III-heparin (AT-H),
activated protein C (aPC), and tissue factor inhibitor (TFPI) pathways (Fig. 1)2. These
regulating systems limit the excessive formation of cross-linked fibrin under hemostatic
conditions. Similarly, anti-plasmin (AP), plasminogen activation inhibitor (PAI), and
thrombin activatable fibrinolysis inhibition pathways prevent clot lysis until coagulation is
complete (Fig 2).
The specificity of interactions, both molecular and cellular, involved in these complex
processes supports the concept that the CF system displays global effects through
emergence of localized events. The CF system may be viewed as a multi-component
molecular machine6, in which individual components are linked through multiple
feedback and feedforward loops. This introduces non-linear relationships among the
components. A static diagram such as the classically portrayed coagulation pathway
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(Figure 1) cannot adequately describe this dynamic evolutionary network. Moreover, the
effects of several disease states on the imbalances in the CF system are difficult to
understand. For example, the influence of diseases that favor coagulation (e.g.
coronary artery disease, disseminated intravascular coagulation, cerebrovascular
accidents, and venous thrombosis), or those that impair coagulation (e.g. hemophilias,
thrombocytopenias, and von Willebrand disease) remain poorly characterized in terms
of the interactions of all components in the system over time.

Figure 2: Fibrinolytic Cascade and Inhibitors- Inhibitors are denoted by circles. The fibrinolytic pathway is
initiated by tPA activation of Plasminogen. Plasmin hydrolyzes fibrin. Plasmin and fibrin catalyze the conversion
of Plasminogen to Plasmin.

To date, most computational models of the coagulation system have focused on using
ordinary or partial differential equations (ODEs and PDEs) 15-18. The differential
equations describe the change in the states of the variables of the system over time and
are derived from known or hypothesized kinetics. ODE models can readily simulate
coagulation in vitro as it is a relatively homogenous system3-5; however, such models
face significant limitations when modeling in vivo hemostasis because of complicating
factors such as non-stationarity, spatial heterogeneity and the effects of blood flow6.
Therefore, derivation of differential equations suitable for in vivo modeling becomes
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problematic. Additionally, these models are incapable of demonstrating the
randomness and variability within the system as it normally operates.

In order to address the shortcomings associated with ODE models, we present the
application of a computational systems biology approach using agent-based modeling
and simulation (ABMS) to understand the CF system and predict selected outcomes.
ABMS provides a powerful alternative to differential equations7-9. ABMS is a relatively
new modeling paradigm derived from cellular automata (CA)10, 11. ABMS has mobile
autonomous entities (agents) that can move through a 2-D grid. Each agent is allowed
to assume a finite number of states, determined by a pre-defined set of rules. Every
agent is individually updated at the end of each operating period according to the preset rules. The rules are a function of the current state of the agent and the state of its
neighbors.

As a first step, we created a model designed to simulate the in vitro environment. The
goal of the model is to simulate common lab tests performed on patients.
Materials and Methods:
In this in vitro model all substrates, reactions, and products from the intrinsic, extrinsic,
common, fibrinolytic, AT-H, TFPI, PC, AP, PAI, and TAFI pathways have been included.
In order to create realistic simulations, physiologic concentrations of factors were used
in the in silico experiments. The rates associated with the reactions were taken from
the literature and were assumed to be performed in saturating phospholipid and calcium
conditions. The simulations were designed to test experimental conditions that create
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interesting thrombin profiles or to demonstrate perturbations associated with pathology
or pharmaceutical agents associated with the system.
The ABMS approach utilized in this paper uses a two dimensional particle system. The
particle model is one in which particles or ‟agents‟ are able to move about and interact
on a discrete spatial grid. In this case, the agents of the system are the reactants,
enzymes, and products, as defined in the entity table (Appendix 1). Each agent‟s
location on the spatial grid is defined in a two dimensional grid where the agent‟s
location is determined by its x and y coordinates. Each coordinate pair (x, y) is defined
as a unique grid location. Multiple agents may occupy a grid location. A total of 6,241
grid locations (Figure 3) were used in the coagulation simulations and 321 for the
fibrinolytic simulations. A unit time step of the simulation represents 0.01 seconds.

Figure 3: Spatial Grid - The spatial grid is three dimensional in that multiple agents are able to inhabit the same
location.

Each grid location of the ABMS can be empty or can be occupied by one or more
agents . The neighborhood of each agent was defined as all agents located in the
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same grid location. After each time step, an agent was afforded complete freedom to
move in a random manner to one of the adjacent cells. The movement of each agent,
its joining, association, and dissociation with its neighbors are governed by probability
rules. The movement parameter determines the extent of movement (0 implies every
cell is stationary). The joining-association parameter determines the extent of a given
agent interacting with an adjoining agent. The breaking parameter determines the
extent of disruption of con-joined agents . The joining- breaking interactions were
defined by the kinetics of the chemical equations that define the agents‟ behavior
(Appendix 2).

ABMS of Coagulation – To simulate the coagulation phenomenon in vitro the
probability of each interaction event has to be assigned based on biochemical
properties. Each coagulation event is an enzymatic reaction with typical affinities in the
nanomolar to sub-nanomolar range. These high affinities imply that the probability of
conversion is directly correlated to the kinetics of the reactions. The movement
parameter is set at one for every agent in the simulations which means they are free to
diffuse across the grid. The initial configuration of ABMS contained a pre-defined
number of agents for the initial reactants , which is proportional to the known
concentration of agent under normal physiologic conditions. For example, 340,000
antithrombin agents were utilized corresponding to its 3.4 M concentration in normal
plasma. Likewise, 30 agents of VIII were present at initial conditions corresponding to its
physiologic concentration of 0.3 nM. These agents were randomly distributed on the 2-D
grid at time t=0.
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Both the prothrombinase and tenase complexes are formed through a combination of
three factors in vivo. For example, prothrombinase complex is formed by a
combination of prothrombin, factor Xa and factor Va, while the intrinsic tenase complex
is formed when factors VIIIa and IXa combine with factor X. These three body
complexes are not directly simulated in ABMS, as in vivo, these complexes must arise
through sequential combination of two molecules and thus, we utilized a sequential twobody collision approach to generate each complex.

Figure 4: Computational Algorithm- The simple computational algorithm that controls the flow of the simulations.

The spatial grid is in the shape of a square allowing the agents to interact and bounce
off the edge of the grid. The system was acellular with complete absence of platelets,
RBC, or WBC representing plasma that is used in coagulation/fibrinolysis assays. The
reactions and rate constants represented by the rule table are representative of
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experimentally observed rates under saturating phospholipid and calcium
concentrations. Figure 4 illustrates the algorithm used for running the simulations.

Computational Hardware and Software – A software package designed to run ABMS
was utilized to design and perform the simulations (Netlogov4.0412). The user
determines the subset of, reactions, reactants and coagulation factors, the probabilities
of reactions, initial agent concentrations, and termination conditions for each simulation.
The concentration of every coagulation factor was stored every 100 time steps (1 virtual
second). All simulations were carried out on an Intel based desktop personal computer
running Microsoft Windows XP. Because of the nature of the software and the large
number of interactions, each simulation took between 1-72 hours depending on the
initial and stop conditions.

Coagulation Simulations – Unless otherwise stated, modeling of the system was
performed under conditions that simulated the mean physiologic concentrations of each
soluble factor involved in the cascade, which were derived from literature reports
(Appendix 3). The model was designed to simulate volumes of 2mL using 6241 grid
locations. The model was tested under 1) conditions in which the type of agents was
limited to a small subset of the coagulation factors or 2) conditions in which all the
coagulation factors were represented. The simulations were designed to test
experimental conditions that demonstrate pathology associated with the system. Each
simulation was run ten times. Comparisons between the ABMS output and
experimental data were used to determine the validity of the system.
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Both PT and aPTT experiments were terminated when 99% of the initial fibrinogen was
converted to fibrin monomers. When running PT experiments, an additional end
condition of 135 seconds was defined. This time equates to an INR > 10 which is a
commonly reported value in clinical laboratories. Similarly, an end condition of 150
seconds was defined for aPTT experiments.

Fibrinolysis Simulations – Unless otherwise stated, modeling of the system was
performed under conditions that simulated the mean physiologic concentrations of each
soluble factor involved in fibrinolysis, which were derived from literature reports in
human blood under normal physiological conditions (Appendix 3). Fibrinolysis
experiments are typically done on volumes of 100µL which corresponds to 321 grid
locations. The model was tested under conditions in which the type of agents was
limited to a small subset of the CF factors. Given the time scale of hours rather than
minutes, each simulation was run five times. Comparisons between the ABMS output
and experimental data were used to determine the validity of the system.

Simulations - Simulating the CF system is challenging because not all interactions have
been fully defined. Further, whether ABMS technology can reliably predict the functional
behavior of the CF system has not been established. Thus, to establish that validity of
ABMS in understanding the CF system, three sets of simulations were performed. The
first set of experiments tested the applicability of the CF model. The second set of
experiments attempted to simulate perturbations of these pathways so as to mimic
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clinical disease states by measuring prothrombin time (PT) and activated partial
thromboplastin time (aPTT). Finally, the third set of experiments measured the effects of
pharmaceutical agents upon these CF pathways

Statistical Analysis –The statistical package R v2.7.0 was used for all statistical
calculations. All confidence intervals in the paper are at the 95% level.

Results:
Three sets of simulations were performed to: 1) Validate the model using previously
published data and known in vivo and in vitro conditions associated with the intrinsic,
extrinsic, common pathway, and fibrinolysis; 2) Simulate perturbations of pathways
mimicking clinical disease states by measuring prothrombin time (PT) and activated
partial thromboplastin time (aPTT) as well as; 3) Measure the effects of pharmaceutical
agents upon these pathways.

Model Validation Simulations - Model validation was performed through the first set of
simulations. Through successful reproductions of the in vitro experiments performed by
van‟t Veer et al.13, 14, Wang et al.15, Christensen et al.16, Masson et al.17, Bajzar et al.1
and in silico experiments performed by Hockin et al.18 as described below, the behavior
of the ABMS was validated.

Simulation of the Extrinsic Pathway Without Regulation - The intrinsic and extrinsic
pathways can function independently of each other to generate a clot. In vivo, the most

74

important pathway for the initiation of clot formation is the extrinsic pathway (abnormally
low levels of PK, HMWK, or XII have no effects on bleeding times); therefore the initial
simulations are focused on validating the behavior of the extrinsic pathway. To validate
the use of ABMS in predicting the functional property of the extrinsic pathway, only
seven agents were introduced on the rectangular grid including TF-VIIa, V, VIII, IX, X,
TFPI, AT, and PC. TF-VIIa complex initiates coagulation resulting in the formation of
factor IIa, the level of which is proportional to the level of clot formation under normal
conditions. TFPI, AT, and PC were used to assess the ability of ABMS to reflect system
regulation.

The first simulation was performed in the context of the procoagulants (TF-VIIa, II, V,
VIII, IX, and X). Formation of thrombin was initiated by TF-VIIa at various
concentrations (5pM, 30pM, and 130pM). At each concentration of TF-VIIa, the most
notable characteristic of the procoagulant simulation (Figure 5a) is its biphasic behavior
composed of an initiation phase followed by a propagation phase. This sigmoidal
growth profile is characteristic of multi-step reactions. The increasing concentrations of
TF-VIIa resulted in shortening initiation times, arbitrarily defined as the time needed to
form 20 nM of IIa (Table 1). Additionally, an increased maximum rate of IIa formation
during the propagation phase was observed as a function of concentration (Table 2).
The sigmoidal factor IIa growth profile coupled with a dependence on initiator
concentration suggest that ABMS may be expected to simulate the coagulation
cascade*.

*Elimination of rules 33 or 27, which relate to the generation of thrombin from Xa and generation of Xa from TF-VIIa,
respectively, suppressed all thrombin formation under all conditions (data not shown).
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Table 1: Initiation phase length (s). Initiation time is defined as the time it takes to form 20nM of IIa. The
initiation time is a function of the TF-VIIa initiating concentration. The combinations of TFPI and AT have the
largest effect on the initiation times.

5pM

30pM

130pM

NI

38.7+/-7.06

20.7+/-2.31

11.8+/-1.57

TFPI

74.5+/-21.04

39.1+/-10.38

16.2+/-4.11

AT

59.7+/-10.75

27.9+/-4.44

14.6+/-3.20

50.8+/-13.83

34.2+/-13.04

TFPI + AT N/A

Table 2: Maximum thrombin generation rate (nM IIa /s). The maximal rate is a function of the TF-VIIa
initiating concentration. The combinations of TFPI and AT have the largest effect on thrombin generation rates.

5pM

30pM

130pM

NI

43.8+/-6.22

82.7+/-3.50

110.3+/-6.54

TFPI

30.2+/-5.46

41.0+/-5.24

68.5+/-9.16

AT

19.1+/-5.80

47.0+/-6.03

85.9+/-5.92

13.4+/-3.53

37.4+/-7.55

TFPI + AT 0.7+/-1.48
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Figure 5: Total thrombin generation with and without inhibitors. A-C: The initiating concentrations of TFVIIa illustrated: circle = 130 pM, triangle = 30 pM, and square = 5 pM. A) No inhibitors present B) 2.5nM TFPI
present C) AT 3.4µM present D) The initiating concentration of TF-VIIa is 5pM in the presence of 65nM PC. TM
concentration: circle = 0 pm, triangle = 0.1pm and square = 10pm. N=10.

Simulation of the Extrinsic Pathway With Regulation- To assess whether ABMS
simulates the regulatory aspects of coagulation, we examined the behavior of the
system in the presence of TFPI, AT, and PC. When TFPI at 2.5 nM (TFPI‟s normal
plasma concentration) is added to the titrations observed in Figure 5a, a significant
extension of the initiation phase is observed with only small effect on the maximal rate
of propagation. As seen experimentally, adding TFPI to samples with TF-VIIa below
100pM leads to a doubling of the initiation time (Figure 5b, Tables 1&2). It is important
to note that addition of TFPI as the only regulator of the extrinsic pathway does not alter
the final level of factor IIa, and hence the clot, formed in the process.
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To assess the effect of adding an irreversible coagulation inhibitor, AT was introduced
at a concentration of 3.4 M (AT‟s normal plasma concentration) to the titrations
observed in Figure 5a. The addition of AT leads to formation of characteristic bell
shaped curves for the formation of IIa at all concentrations (Figure 5c). These profiles
are similar to those found in studies of coagulation in plasma. The AT has little effect on
either the initiation time rate or the maximal rate of thrombin generation during the
propagation phase at 130pM concentrations of TF-VIIa (Tables 1&2) suggesting that AT
alone is an effective regulator of coagulation primarily at low levels of TF-VIIa. This is in
line with experiments in plasma, which show that AT is not effective in rapidly reducing
a bolus of factor IIa stemming from its slow kinetics.

The last important inhibitor for the coagulation system is PC. Figure 5d demonstrates
the effects of 65 nm PC and TM on the thrombin generated by the extrinsic system.
Starting with an initial concentration of 5pM TF-VIIa, thrombin is plotted against time as
TM concentration is varied (0, 0.1, and 10 nm). PC in the absence of TM and at low TM
concentration has minimal effects. At high concentrations of TM, the rate of thrombin
generation during the propagation phase is decreased. Furthermore, a significant
interruption of the propagation phase occurs leading to a biphasic propagation phase;
thus, activation following thrombin generation illustrates the dynamic feedback
characteristic of the PC pathway.
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Simulation of Hyper Anticoagulation - To assess whether a pro-thrombotic state can be
reliably controlled by either of the two natural regulators, the concentrations of AT and
TFPI were increased to levels dramatically higher than normal at a fixed TF-VIIa
concentration (130pM). Figure 6a demonstrates the effects of increased concentrations
of TFPI on IIa formation from 1.25 nM (½ baseline) up to 25 nM (20x baseline). There
is a progressive elongation of the initiation times with only minimal decrease in reaction
rates. The maximal levels of IIa reached for all concentrations of TFPI is the same
suggesting that even a 20-fold increase in TFPI is not able to shut down the procoagulant signal. On the contrary, increasing AT concentrations from 1.7 M (½
baseline) up to 20.4 M (6x baseline) does not alter the initiation time dramatically (Fig.
6b), but essentially shuts off the pro-coagulant signal. As AT concentrations increase,
the total amount of IIa generated decreases. Initiation times and maximal IIa rate are
decreased as well. At AT levels >7x baseline, IIa formation is totally inhibited (data not
shown). These results support the concept that the AT regulatory system is expected to
play a major role in anticoagulation therapy.

Fibrinolytic Simulations -The fibrinolytic simulations were limited to the following agents:
Pg, mPG, P, tPA, fibrin, PAI, AP, TAFI, II, and TM. Plasminogen activation by tPA is
stimulated by fibrin and augmented by plasmin catalyzed feedback modification of fibrin.
A modified version of plasminogen designed to simulate the Glu1 and Lys78 form of
plasminogen (mPG) was utilized. mPG does not generate plasmin thereby attenuating
the self-activating positive feedback associated with plasmin. In order to investigate the
rate of plasminogen activation, the concentration of the mPG is plotted against time
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under various conditions (Fig 7). The control group has neither aTAFI nor PG.
Therefore, the rate of mPG activation is solely related to tPA concentration. The group
associated with P. At early time points, mPG consumption is equivalent among all the
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Figure 6: Figure 4: Total thrombin generation profile with 130pM TF-VIIa with AT & TFPI. A) thrombin
generation profile with 130pM TF-VIIa at various levels of TFPI. Circle = ½ baseline concentration, + = baseline,
large plus = 2x baseline, X = 4x baseline, x = 6x baseline, square = 10x baseline, and x = 20x baseline B) thrombin
generation profile with 130pM TF-VIIa at various levels of AT. circle = ½ baseline concentration, triangle = baseline,
plus = 2x baseline, X = 3x baseline Insert: thrombin generation profile with 130pM TF-VIIa at 4x AT (circle) and 6x AT
(squares). N=10.

with PG and no ATAFI evaluate the positive feedback associated with P. The ATAFI
groups investigate the effects of ATAFI on the suppression of the positive feedback is
accelerated. This effect is attenuated by aTAFI and is eliminated at aTAFI
concentrations of 5nM resulting in a curve virtually indistinguishable from the control.

Antiplasmin inhibits fibrinolysis by rapidly forming a reversible bond with plasmin. In
order to investigate the kinetics associated with AP, the unbound P concentration was
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plotted against time with AP and P present in equimolar concentrations. Figure 8 shows
the majority of P is bound within 5 seconds.

Figure 7: Effect of aTAFI on the activation of plasminogen. The concentration of uncleaved modified
plasminogen is plotted against time. Fibrinogen was present in 3µM and 200nM modified plasminogen. The
reactions were initiated by 5nM tPA. Controls (circle) lacked P and aTAFI. P 5nM and aTAFI (square = 0nM,
triangle = 1nM and plus = 5nM) were present in the experimental groups. The control and 5nM aTAFI groups
overlap and cannot be distinguished. N=5.
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Figure 8: Plasmin-Antiplasmin binding kinetics. Equimolar concentrations (1000nM) of Plasmin and
Antiplasmin were combined. Unbound Plasmin concentration is plotted over time. N=5.

PAI inhibits tPA by reversibly binding tPA. The rate of PG activation by tPA was used to
determine the effectiveness of PAI. Following two minutes of equilibration of various
tPA concentrations +/- PAI with fibrin, PG was added (Figure 9). The rate of initial PG
activation was plotted vs. time. The presence of a constant amount of PAI induces the
formation of tPA-PAI complexes and a concomitant decrease in the amount of tPA that
can bind to fibrin. As a result of this relative decrease in tPA concentration, the rate of
plasminogen activation is decreased.

Figure 10 demonstrates the kinetics of TAFI activation by IIa-TM. TM concentration
was varied over different concentrations of TAFI in the presence of IIa (1nm) . The
initial rate of TAFI activation was plotted vs. time. The rate of TAFI activation is
significantly increased in the presence of TM.
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Figure 9: Effect of PAI on the rate of plasminogen activation by tPA. The rate of activation of plasminogen
was plotted vs. tPA concentration. Various concentrations of tPA (5, 10, 15, 20, 25, 38, 50, 100, and 150 IU/mL)
were combined with 200nM plasminogen and 3µM fibrin in the absence (open circles) and presence of 20 IU/mL
PAI (closed circles). In the presence of PAI, the velocity curve is shifted to the right indicating delayed
plasminogen activation. N=5.

Figure 10: Thrombomodulin concentration dependence of initial rates of TAFI activation. The thrombin
concentration is 1 nM. The TM concentration was varied from 1nM, 6 nM to 50nM. The TAFI concentration was
varied from 0.26 (circles), 0.52 (square), 1 (triangle), to 2 (plus) µM (from bottom to top). TM increases the
catalytic efficiency of TAFI activation by IIa. N=5.
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To determine the effects of aTAFI on tPA mediated fibrinolysis, lysis assays were
performed on a system of purified fibrinolytic components in the presence and absence
of 63 nM aTAFI. The system was composed of: fibrinogen (3 uM), tPA, (5nM) and
plasminogen (5nM). Lysis times were defined as the time required to lyse half of the
fibrin. The lysis times were 33m +/- in the absence of aTAFI and 70m +/- in the
presence of aTAFI.

Simulation of Common Coagulation Tests- The results described above of ABMS in
simulating the extrinsic pathway indicated that it might be possible to reliably simulate
the entire clotting cascade. Two in vitro tests, the prothrombin time (PT) and the
activated partial thromboplastin time (aPTT), are commonly utilized in assessing the
coagulation status of patients. Depending on the initiator, either TF (PT) or kaolin
(aPTT), the test probes the fidelity of the extrinsic or the intrinsic pathway as a part of
the whole cascade. As these test are performed on human plasma , except for the
bolus of the initiator, all factors of the clotting cascade are typically present at their
normal plasma levels (Appendix 3). In order to simulate plasma, the full CF system
(utilizing all 106 rules and 57 agent types) was included in the simulations using the
normal mean concentration for the factors. In order to initiate coagulation in the PT
assay, excess TF (100,000 agents) was introduced. This TF concentration is 100x that
of VII; therefore the initial reaction is driven by VII concentrations. Figure 11 shows the
formation of clot in the PT assay. In a manner similar to plasma PT, the ABMS displays
initiation, propagation and termination of the coagulation signal. A median clotting time
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of 13.7s +/- 1.2 (normal in vitro PT is between 12-15s). These results suggest that the
clinically utilized PT assay can be readily simulated using ABMS.

Similarly, the fidelity of the intrinsic pathway was tested by performing aPTT
simulations. In order to initiate coagulation, the intrinsic pathway is activated by using
excess kaolin (100,000 agents) to activate factor XII. The results were found to be
similar to the PT assay with the exception of a longer initiation phase (Fig 11); the final
clot level and the rate of clot formation were identical to the simulated PT assay. A
median clotting time of 29.7s +/- 2.0 s was calculated for the simulated aPTT test, which
compares favorably with the normal in vitro aPTT of 24-40s. Thus, all the parameters
characteristic of both the PT and aPTT assays, including the clot time, rate and level of
clot formation, support the conclusion that ABMS can reliably model the entire blood
coagulation cascade.

Simulation of Clinical Pathologies - The next step in analyzing the behavior of the ABMS
is simulating clinical pathologies. In the first scenario, we simulated hemophilia B
(Christmas disease). Hemophilia B is a disease in which patients have an increase in
their aPTT times, spontaneous hemorrhages, and difficulty clotting after minor injuries
due to abnormal levels of Factor IX. In order to simulate Hemophilia B, the system was
perturbed by examining the effects of decreased concentration of Factor IX on the aPTT
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Figure 11: Figure 9: Clot as a function of time when measuring the PT (circles) and aPTT (plus) of normal
plasma. The initiation, propagation and termination of clot formation are demonstrated. aPTT times are ~2x
longer than PT times due to longer initiation phase. N=10.

assay described in the previous section. In this case, the full CF system was included
in the simulations using the normal mean concentration for the factors with the
exception of Factor IX. The clinical assay used to monitor Hemophilia B is the aPTT.
The aPTT times of Hemophilia B patients was simulated by decreasing the initial Factor
IX concentrations otherwise using the full system as described above (Figure 12a). Mild
hemophilia is defined as Factor IX activity 10-40% of normal with resultant aPTT times
that are normal or only slightly increased. Figure 12a demonstrates the range of aPTT
to be between 30-40 s. Moderate hemophilia is defined as factor IX activity between 1
and 10%. Using 2% of normal Factor IX levels gives aPTT times equal to 101.9s +/23.88. Severe hemophilia is defined as Factor IX levels < 1%. At this Factor IX
concentration, clot formation was totally inhibited and the aPTT times were greater than
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160s as the simulations were terminated. These aPTT times are an accurate reflection
of those seen clinically in Hemophilia B patients.

Another interesting clinical condition is one in which AT binding to heparin is impaired.
Despite normal plasma AT levels, impaired AT-H binding is associated with a
hypercoagable state characterized by an increased risk of thromboembolic disease as
well as intrauterine fetal demise (IUFD)19-23. This condition was simulated by changing
the joining parameter that determined whether AT and H react when they collide
(increasing it to 10x baseline to decreasing it to 1/1000 baseline). A concentration of
heparin (H8000) that leads to impaired clotting was used to demonstrate the effect of
the change in AT-H binding. The clinical test used to measure the effects of heparin is
the aPTT. Figure 12b demonstrates the effects of changing the AT-H binding
probability from 10x baseline to 1/1000 baseline. The aPTT time decreased from >
160s, in the case of 10x baseline, to clotting times that are the equivalent of blood with
no heparin, in the cases of 1/100 baseline and 1/1000 baseline binding probability. The
results demonstrate that decreasing the AT-H binding probabilities leads to a
hypercoagulable state.
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Figure 12: aPTT times under pathophysiologic conditions. A) Hemophilia B- As factor IX concentration
decreases aPTT times increase until clotting is totally inhibited in severe hemophilia (<1% baseline IX
concentrations) B) AT-H binding deficiency- Impaired binding of heparin to AT returns aPTT times to baseline.
Increasing binding probabilities lead to total inhibition of clotting. N=10.

Pharmacologic Simulations - Pharmaceutical agents, e.g., heparin and warfarin, are
routinely used to modulate the coagulation state of patients. To test whether the effect
of these agents can be incorporated in the coagulation model, simulations were
performed in the presence of heparin and warfarin. These results show that drugs such
as heparin, warfarin, activated protein C, etc… can easily be simulated using the model.
Figure 13a demonstrates the effects of therapeutic and supra-therapeutic heparin on
the aPTT times. Heparin is a commonly used inpatient drug given via IV for anticoagulating patients for DVT, PE, and MI. Heparin serves to activate AT thereby
increasing the reaction rate a thousand-fold. As heparin concentration increases from
3000 Units to 11,000 Units so do the aPTT times from ~30s to the maximum of 160s in
a non-linear manner. As is well known to clinicians, the simulations demonstrate that
the change in concentration from therapeutic levels (8000U) to super-anticoagulated
levels (11,000 Units) is very small, and can make heparin titrations problematic.
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Similarly, Figure 13b demonstrates the effects of therapeutic and supra-therapeutic
levels of the medication warfarin. Warfarin is a common medication used in the
outpatient setting, given by mouth, to patients that require long term anti-coagulation. .
Warfarin inhibits the vitamin K-dependent formation of fully functional coagulation
factors. The clinical test used to monitor the effects of warfarin is the PT time. The
consequences of warfarin administration were simulated by decreasing concentrations
of vitamin K dependant factors (II, VII, IX, and X) from 90% baseline levels to 1%
baseline levels. As expected, decreasing levels of the coagulation factors led to
increasing PT times in a non-linear manner until the maximum of 150s is reached.

Discussion:
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The initial results of this paper indicate that the in vitro CF system can be readily
simulated using ABMS. The model used in this paper successfully simulated aPTT and
PT times at normal physiologic conditions, abnormal physiologic conditions (hemophilia
B and AT-H binding defect), and after pharmaceutical interventions (warfarin and
heparin). Furthermore, the emergence of a threshold for the generation of thrombin
was conclusively demonstrated. The non-linearities of the CF system were captured
using this ABMS. The ability of ABMS to simulate results that are found in clinical
studies was demonstrated. The ability to predict clinical trials would be an invaluable
tool for clinical research. The ability to vary initial concentrations of CF factors that
mimics what would be seen in a normal population combined with the error bars
associated with the data are unique to ABMS and provide the ability to simulate in vitro
experiments and clinical trials.

The CF systems interact strongly at the molecular and cellular level; they thereby
operating as a coherently linked system, to generate several pathological and
physiological responses. The highly complex CF system presents a challenging
problem of identifying the root cause of many known coagulation defects. To date the
contribution of each system as a part of the network has not been attempted. We have
developed an ABMS of the CF cascade that allows systematic evaluation of each of its
components – individually and as a complex entity. The model allows a comprehensive
analysis of the CF cascade that provides insight into understanding and predicting the
pathophysiologic responses arising from variations in molecular and cellular
components.
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Computational systems biology is a rapidly growing field that provides tools to analyze
and understand dynamic evolutionary networks such as the one presented by CF9-11. A
major advantage of this approach is its rapid, real time analysis of multiple biological
systems, each of which can be a highly coordinated independent network interacting
with other networks in the group at one or more branch points. These independent
networks can be thought of as small molecular machines, which work co-operatively to
form a large, multi-component molecular machine producing one or more physiological
responses. Understanding the mechanism and co-operativity of these networks as well
as predicting the physiological response to appropriate pharmaceutical agents is an
extremely difficult and intricate task. Advanced systems biology techniques, e.g.,
computational technology, hold major promise in achieving this goal and consequently
may be extremely useful in understanding patho-physiological conditions and their
treatment.

ABMS allows a real time analysis of the coagulation system that is difficult if not
impossible to obtain through in vivo experiments. Additionally, ABMS provides an
opportunity to understand the complex interplay among the various subsystems at any
point in time. Reductionist in vitro experimental techniques have allowed a detailed
understanding of the individual chemical reactions involved in the process of
coagulation. ABMS represents a non-reductionist approach of studying the biologic
process as a whole, while retaining the information at an individual level. The
information obtained by studying the individual reactions is used as the basis for the
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rules governing the updating of the ABMS. The advantages of ABMS include the ability
to simulate the non-linear aspects of the coagulation system. As the agents are able to
change state based on their environment, the model adapts and accounts for changes
such as dearth/excess of coagulation inhibitors, absence of factors, or therapeutic
interventions. The time required to update the model is one disadvantage of ABMS as it
is computationally expensive for large systems with many elements; however a specific
advantage of this model is its ability to allow for the addition of newly discovered
mediators, which can impact upon both coagulation and inflammation. More importantly,
the model has a high probability of exhibiting emergence in which its outputs produce
unanticipated results, which can then be biologically confirmed. Such properties are
particularly useful in the discovery of diagnostic and therapeutic interventions.
Comprehensive modeling of the traditional coagulation cascade allows virtual
experimentation of the effects of local and systemic injury on coagulation.

Only by creating models, which account for these seemingly diverse but clearly
connected processes can one hope to improve our overall understanding of the
coagulation process and to create more powerful diagnostic and therapeutic options.
We have employed an ABMS in our current approach due to the potential ability to
quantitatively analyze individual components of each system at every point of
simulation. ABMS is a dynamic modeling and simulation tool that allows the study of
dynamic non-linear networked systems. ABMS represents a non-reductionist approach
of studying the biologic process as a whole, while retaining the information at an
individual level. The complexity of the system has stymied experimental efforts to gain
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a system level understanding of the coagulation cascade and its subnetwork
components. ABMS may readily provide elucidation of the pathophysiology of diseases
related to the coagulation system. The model may also provide insight into individual
disease processes such as genetic and acquired disorders of coagulation.

A major advantage with ABMS is the ability to monitor each coagulation factor as
„clotting‟ proceeds. This implies that the effect of a large number of factors that
influence coagulation (e.g. natural and pharmaceutical anticoagulants, natural and
pharmaceutical fibrinolytic agents, and intrinsic and external inflammation mediators)
can be simulated readily. These ABMS are expected to provide information on the
overall progress of clotting as well as on individual coagulation factor as a function of
time. Thus, ABMS of the coagulation cascade affords the ability to simulate the effect of
heparins / low molecular weight heparins, coumadins, and factor Xa / thrombin inhibitors
at a systemic level for the first time.

Computational modeling allows the creation of rapid and inexpensive virtual laboratories
to generate and test hypotheses13, 14. More importantly, simulations provide clinical
tools to design and test novel therapeutic strategies, while affording opportunities to
predict adverse events during drug development. Additionally, bedside simulations will
allow personalized medicine in that replacement factor concentrations can be calculated
for individual hemophiliac patients, heparin doses can be titrated, etc… Additional
applications of the model include discovery of new mediators, understanding of proximal
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and distal effects of interactions between systems, discovery of new diagnostic and
therapeutic options, and development of new software and algorithms for simulation.

94

References
1.
Bajzar L, Morser J, Nesheim M. TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation
and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex. J Biol Chem
1996;271:16603-8.
2.
Monroe DM, Hoffman M. What Does It Take to Make the Perfect Clot? Arterioscler Thromb Vasc
Biol 2006;26:41-8.
3.
Zhu D. Mathematical modeling of blood coagulation cascade: kinetics of intrinsic and extrinsic
pathways in normal and deficient conditions. Blood Coagul Fibrinolysis 2007;18:637-46.
4.
Hockin MF, Jones KC, Everse SJ, Mann KG. A Model for the Stoichiometric Regulation of Blood
Coagulation. J Biol Chem 2002;277:18322-33.
5.
Jones KC, Mann KG. A model for the tissue factor pathway to thrombin. II. A mathematical
simulation. J Biol Chem 1994;269:23367-73.
6.
Bonabeau E. Agent-based modeling: methods and techniques for simulating human systems.
Proc Natl Acad Sci U S A 2002;99 Suppl 3:7280-7.
7.
An G. Agent-based computer simulation and sirs: building a bridge between basic science and
clinical trials. Shock 2001;16:266-73.
8.
Bankes SC. Agent-based modeling: A revolution? PNAS 2002;99:7199-200.
9.
Bonabeau E. Agent-based modeling: Methods and techniques for simulating human systems.
PNAS 2002;99:7280-7.
10.
Rider RE. Aspects of Ulam: From Cardinals to Chaos. Science 1989;246:134-.
11.
Wolfram S. Cellular Automata and Complexity: Collected Papers: Westview Press; 1994.
12.
Wilensky U. NetLogo. Evanston, IL: Center for Connected Learning and Computer-Based
Modeling, Northwestern University; 1999.
13.
van `t Veer C, Mann KG. Regulation of Tissue Factor Initiated Thrombin Generation by the
Stoichiometric Inhibitors Tissue Factor Pathway Inhibitor, Antithrombin-III, and Heparin Cofactor-II. J
Biol Chem 1997;272:4367-77.
14.
van `t Veer C, Golden NJ, Kalafatis M, Mann KG. Inhibitory Mechanism of the Protein C Pathway
on Tissue Factor-induced Thrombin Generation. SYNERGISTIC EFFECT IN COMBINATION WITH TISSUE
FACTOR PATHWAY INHIBITOR. J Biol Chem 1997;272:7983-94.
15.
Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A Study of the Mechanism of Inhibition of
Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor. J Biol Chem 1998;273:27176-81.
16.
Christensen U, Bangert K, Thorsen S. Reaction of human alpha2-antiplasmin and plasmin
stopped-flow fluorescence kinetics. FEBS Lett 1996;387:58-62.
17.
Masson C, Angles-Cano E. Kinetic analysis of the interaction between plasminogen activator
inhibitor-1 and tissue-type plasminogen activator. Biochem J 1988;256:237-44.
18.
Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood
coagulation. J Biol Chem 2002;277:18322-33.
19.
O'Ddonnell JS, Hinkson L, McCarthy A, Manning R, Khan A, Laffan MA. Antithrombin Nagasaki
(Ser 116 to Pro): a rare antithrombin variant with abnormal heparin binding presenting during
pregnancy. Blood Coagul Fibrinolysis 2006;17:217-20.
20.
Tsiang M, Jain AK, Gibbs CS. Functional Requirements for Inhibition of Thrombin by
Antithrombin III in the Presence and Absence of Heparin. J Biol Chem 1997;272:12024-9.
21.
Owen MC, Borg JY, Soria C, Soria J, Caen J, Carrell RW. Heparin binding defect in a new
antithrombin III variant: Rouen, 47 Arg to His. Blood 1987;69:1275-9.
22.
Bauters A, Zawadzki C, Bura A, et al. Homozygous variant of antithrombin with lack of affinity for
heparin: management of severe thrombotic complications associated with intrauterine fetal demise.
Blood Coagul Fibrinolysis 1996;7:705-10.

95

23.
Dewerchin M, Herault J-P, Wallays G, et al. Life-Threatening Thrombosis in Mice With Targeted
Arg48-to-Cys Mutation of the Heparin-Binding Domain of Antithrombin. Circ Res 2003;93:1120-6.
24.
O'Brien DP, Kemball-Cook G, Hutchinson AM, et al. Surface plasmon resonance studies of the
interaction between factor VII and tissue factor. Demonstration of defective tissue factor binding in a
variant FVII molecule (FVII-R79Q). Biochemistry 1994;33:14162-9.
25.
Krishnaswamy S. The interaction of human factor VIIa with tissue factor. J Biol Chem
1992;267:23696-706.
26.
Shobe J, Dickinson CD, Edgington TS, Ruf W. Macromolecular Substrate Affinity for the Tissue
Factor-Factor VIIa Complex Is Independent of Scissile Bond Docking. J Biol Chem 1999;274:24171-5.
27.
Butenas S, Mann KG. Kinetics of human factor VII activation. Biochemistry 1996;35:1904-10.
28.
Baugh RJ, Broze GJ, Jr., Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by
tissue factor pathway inhibitor. J Biol Chem 1998;273:4378-86.
29.
Baugh RJ, Dickinson CD, Ruf W, Krishnaswamy S. Exosite interactions determine the affinity of
factor X for the extrinsic Xase complex. J Biol Chem 2000;275:28826-33.
30.
Baugh RJ, Krishnaswamy S. Role of the activation peptide domain in human factor X activation
by the extrinsic Xase complex. J Biol Chem 1996;271:16126-34.
31.
Bergum PW, Cruikshank A, Maki SL, Kelly CR, Ruf W, Vlasuk GP. Role of zymogen and activated
factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex by
recombinant nematode anticoagulant protein c2. J Biol Chem 2001;276:10063-71.
32.
de Moerloose P, Bounameaux HR, Mannucci PM. Screening test for thrombophilic patients:
which tests, for which patient, by whom, when, and why? Semin Thromb Hemost 1998;24:321-7.
33.
Bom VJ, van Hinsbergh VW, Reinalda-Poot HH, Mohanlal RW, Bertina RM. Extrinsic activation of
human coagulation factors IX and X on the endothelial surface. Thromb Haemost 1991;66:283-91.
34.
Tankersley DL, Finlayson JS. Kinetics of activation and autoactivation of human factor XII.
Biochemistry 1984;23:273-9.
35.
Gailani D, Broze GJ, Jr. Factor XI activation in a revised model of blood coagulation. Science
1991;253:909-12.
36.
Rawala-Sheikh R, Ahmad SS, Ashby B, Walsh PN. Kinetics of coagulation factor X activation by
platelet-bound factor IXa. Biochemistry 1990;29:2606-11.
37.
Lollar P, Parker ET, Fay PJ. Coagulant properties of hybrid human/porcine factor VIII molecules. J
Biol Chem 1992;267:23652-7.
38.
Fay PJ, Smudzin TM. Characterization of the interaction between the A2 subunit and A1/A3-C1C2 dimer in human factor VIIIa. J Biol Chem 1992;267:13246-50.
39.
Fay PJ, Beattie TL, Regan LM, O'Brien LM, Kaufman RJ. Model for the factor VIIIa-dependent
decay of the intrinsic factor Xase. Role of subunit dissociation and factor IXa-catalyzed proteolysis. J Biol
Chem 1996;271:6027-32.
40.
Lawson JH, Butenas S, Ribarik N, Mann KG. Complex-dependent inhibition of factor VIIa by
antithrombin III and heparin. J Biol Chem 1993;268:767-70.
41.
Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC. The role of phospholipids and
factor Va in the prothrombinase complex. J Biol Chem 1980;255:274-83.
42.
Higgins DL, Lewis SD, Shafer JA. Steady state kinetic parameters for the thrombin-catalyzed
conversion of human fibrinogen to fibrin. J Biol Chem 1983;258:9276-82.
43.
Monkovic DD, Tracy PB. Activation of human factor V by factor Xa and thrombin. Biochemistry
1990;29:1118-28.
44.
Hill-Eubanks DC, Lollar P. von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of
the factor VIII light chain. J Biol Chem 1990;265:17854-8.

96

45.
Jesty J, Wun TC, Lorenz A. Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa
complex by the tissue factor pathway inhibitor in the presence and absence of heparin. Biochemistry
1994;33:12686-94.
46.
Chuang YJ, Swanson R, Raja SM, Olson ST. Heparin enhances the specificity of antithrombin for
thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite
determinant of factor Xa specificity in heparin-activated antithrombin. J Biol Chem 2001;276:14961-71.
47.
Jordan RE, Oosta GM, Gardner WT, Rosenberg RD. The kinetics of hemostatic enzymeantithrombin interactions in the presence of low molecular weight heparin. J Biol Chem
1980;255:10081-90.
48.
Schoen P, Lindhout T. The in situ inhibition of prothrombinase-formed human alpha-thrombin
and meizothrombin(des F1) by antithrombin III and heparin. J Biol Chem 1987;262:11268-74.
49.
Pixley RA, Schapira M, Colman RW. The regulation of human factor XIIa by plasma proteinase
inhibitors. J Biol Chem 1985;260:1723-9.
50.
Olson ST, Sheffer R, Francis AM. High molecular weight kininogen potentiates the heparinaccelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of
kallikrein. Biochemistry 1993;32:12136-47.
51.
Olson S, Srinivasan K, Bjork I, Shore J. Binding of high affinity heparin to antithrombin III.
Stopped flow kinetic studies of the binding interaction. J Biol Chem 1981;256:11073-9.
52.
Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol
2005;129:307-21.
53.
Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood
1991;78:3114-24.
54.
Bajzar L. Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway. Arterioscler
Thromb Vasc Biol 2000;20:2511-8.
55.
Guimaraes AH, Rijken DC. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in
a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an
internal clot lysis model. Thromb Haemost 2004;91:473-9.
56.
Walker JB, Bajzar L. The Intrinsic Threshold of the Fibrinolytic System Is Modulated by Basic
Carboxypeptidases, but the Magnitude of the Antifibrinolytic Effect of Activated Thrombin-activable
Fibrinolysis Inhibitor Is Masked by Its Instability. J Biol Chem 2004;279:27896-904.

97

Appendix 1:
Entity

Description

XI
XIa
XII
XIIa
XIII
XIIIa
IX
Ixa
VIII
VIIIa
VIIIa1
VIIIa2
IXa-VIIIa
IXa-VIIIa-X
VII
VIIa
II
Iia
X
Xa
V
Va
Va-Xa
TF
TF-VIIa
F
Fm
HMWK
XI
XIa
XII
XIIa
PK
K
AT
AT-Xa
AT-IXa
AT-IIa
AT-TF-VIIa
AT-XIa
AT-XIIa
AT-K
H
AT-H
PC
aPC
Ka
TFPI
TFPI-Xa

Factor XI Activates XII and IX
Activated factor XI
Factor XII (Hagemon factor). Activates XI.
Activated factor XII
Factor XIII. Crosslinks fibrin polymers to form mature clot.
Activated factor XIII
Factor IX (Christmas factor) Activates X. Forms tenase complex
Activated factor IX
Factor VIII. Co-factor of IX – Forms tenase complex
Activated factor VIII
Factor VIIIa spontaneously dissociates into inactive VIIIa1 + VIIIa2
Factor VIIIa spontaneously dissociates into inactive VIIIa1 + VIIIa2
tenase complex - activates X
IXa-VIIIa-X complex
Factor VII. Activates IX and X.
Activated factor VII
Factor II (prothrombin). Activates F, V, VII, XIII
Activated factor II
Factor X. Activates II. Co-factor of V – forms prothrombinase complex
Activated factor X
Factor V. Co-factor of X – forms prothrombinase complex
Activated V
prothrombinase complex – activates II
Tissue Factor. Activates X in combination with VIIa
TF-VIIa complex
Fibrinogen – (Factor I) forms clot after conversion to fibrin and polymerization
Fibrin monomer – forms clot after spontaneous polymerization
high molecular weight kininogen – co-factor for activation of XI, XII, and PK
Factor XI
Activated Factor XI
Factor XII
Activated Factor XII
Prekallikrein
Kallikrein
Antithrombin III – inhibits TF-VIIa, IIa, IXa, XIa, XIIa and Xa
AT-Xa complex
AT-IXa complex
AT-IIa complex
AT-TF-VIIa complex
AT-XIa complex
AT-XIIa complex
AT-K complex
Heparin - co-factor of AT
Antithrombin III - Heparin Complex
Protein C
Activated PC. Inhibits VIIa
Kaolin - activates the contact portion of the intrinsic system
Tissue Factor Pathway Inhibitor - inhibits VIIa-TF, Xa
TFPI-Xa complex
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TF-VIIa-Xa-TFPI
PG
tPA
PAI
tPA-PAI
P
AP
P-AP
TAFI
aTAFI

TF-VIIa-Xa-TFPI complex
Plasminogen
Tissue Plasminogen Activator. Converts PG to P.
Plasminogen Activator Inhibitor. Inhibits tPA.
tPA-PAI complex
Plasmin. Degrades fibrin.
Anti-Plasmin. Inhibits P.
Plasmin - Anti-Plasmin complex
Thrombin Activatable Fibrinolysis Inhibitor- Prevents the P mediated increased rate of
PG activation.
Activated TAFI
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Appendix 2:
#
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

Reaction
VII + TF  VII-TF4, 24, 25
VII + TF  VII-TF4, 24, 25
VIIa + TF  VIIa-TF4, 24, 26
VIIa + TF VIIa-TF4, 24, 26
VIIa-TF + VII  VIIa-TF + VIIa3, 4, 27
Xa + VII  Xa + VIIa3, 4, 27
IIa + VII  IIa + VIIa3, 4, 27
VIIa-TF + X  VIIa-TF-X4, 26, 28
VIIa-TF + X  VIIa-TF-X4, 26, 28
VIIa-TF-X  VIIa-TF + Xa4, 29, 30
VIIa-TF + Xa  VIIa-TF-Xa4, 30, 31
VIIa-TF + Xa  VIIa-TF-Xa4
VIIa-TF + IX  VIIa-TF-IX4, 32, 33
VIIa-TF + IX  VIIa-TF-IX4, 32, 33
VIIa-TF-IX  VIIa-TF + IXa4, 32, 33
XII + Surface + HMWK  XIIa + Surface + HMWK
XII + XIIa  XIIa + XIIa3, 34
PK+ XIIa + HMWK  K + XIIa + HMWK3, 34
XII + K + HMWK  XIIa + K+ HMWK3, 34
XI + XIIa + HMWK XIa + XIIa +HMWK3, 35
XII + XIa  XIIa + XIa3
IX + XIa  IXa + XIa3
X + IXa  Xa + IXa3
XI + IIa  XIa + IIa3
VIIIa + IXa  VIIIa-IXa4, 32
VIIIa + IXa  VIIIa-IXa4, 32
VIIIa-IXa + X  VIIIa-IXa-X4, 32, 36
VIIIa-IXa + X  VIIIa-IXa-X4, 32, 36
VIIIa-IXa-X  VIIIa-IXa-Xa4, 32, 36
VIIIa  VIIIa1 + VIIIa24, 37
VIIIa  VIIIa1 + VIIIa24, 37, 38
VIIIa-IXa  VIIIa1 + VIIIa2 + IXa4, 39
Xa + II  Xa + IIa3, 4, 40, 41
IIa + VIII  IIa + VIIIa3, 4, 28
F + IIa  Fm + IIa3, 42
IIa + V  IIa + Va3, 4, 32, 43, 44
Xa + Va  Xa-Va4, 32
Xa + Va  Xa-Va4, 32
Xa-Va + II  Xa-Va-II4, 32
Xa-Va + II  Xa-Va-II4, 32

Pathway
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Common
Common
Common
Common
Common
Common
Common
Common
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44
45
46
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48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
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64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
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Xa-Va-II  Xa-Va + IIa4, 32
XIII + IIa  XIIIa + IIa3
Xa + TFPI  Xa-TFPI4, 28, 45
Xa + TFPI Xa-TFPI4, 28, 45
TF-VIIa-Xa + TFPI  TF-VIIa-Xa-TFPI4, 28
TF-VIIa-Xa + TFPI  TF-VIIa-Xa-TFPI4, 28
TF-VIIa + Xa-TFPI  TF-VIIa-Xa-TFPI4, 28
AT + Xa  AT-Xa3, 4, 46
AT + TF-VIIa  AT-TF-VIIa 3, 4, 40
AT + IXa  AT-IXa 3, 4, 46, 47
AT + IIa  AT-IIa 3, 4, 48
AT + XIa  AT-XIa3
AT + XIIa  AT-XIIa3, 49
AT + K  AT-K3, 50
AT + H  AT-H51
AT + H  AT-H51
AT-H + Xa  AT-Xa + H46
AT-H + TF-VIIa  AT-TF-VIIa + H40
AT-H + IXa  AT-IXa + H46, 47
AT-H + IIa  AT-IIa + H48
AT-H + XI  AT-XI + H
AT-H + XII  AT-XII + H49
AT-H + K  AT-K + H50
PC + IIa  aPC + IIa14
IIa + TM  IIa-TM14
IIa + TM IIa-TM
PC + IIa-TM  aPC + IIa-TM14
aPC +Va  aPC + Vi14
PG + tPA  P + tPA1, 17, 52, 53
mPG + tPA  tPA1, 17, 52, 53
tPA + Fm  tPA-Fm1, 17, 52, 53
tPA + Fm  tPA-Fm1, 17, 52, 53
tPA-Fm + PG  tPA-Fm-PG1, 17, 52, 53
tPA-Fm + PG  tPA-Fm-PG1, 17, 52, 53
tPA-Fm-PG  tPA-Fm + P1, 17, 52, 53
P + Fm  P1, 17, 52, 53
tPA + PAI  tPA-PAI17
tPA + PAI tPA-PAI17
P + AP  AP-P‟16
P + AP  AP-P‟16
AP-P‟  AP-P16
AP-P‟  AP-P16
aTAFI + Fm  aTAFI-Fm1, 15, 54-56
aTAFI  TAFIi1, 15, 54-56

Common
Common
TFPI
TFPI
TFPI
TFPI
TFPI
AT-H
AT-H
AT-H
AT-H
AT-H
AT-H
AT-H
AT-H
AT-H
AT-H
AT-H
AT-H
AT-H
AT-H
AT-H
AT-H
APC
APC
APC
APC
APC
Fibrinolysis
Fibrinolysis
Fibrinolysis
Fibrinolysis
Fibrinolysis
Fibrinolysis
Fibrinolysis
Fibrinolysis
PAI
PAI
AP
AP
AP
AP
TAFI
TAFI
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IIa+ TAFI  IIa-TAFI1, 15, 54-56
IIa+ TAFI IIa-TAFI1, 15, 54-56
IIa-TM + TAFI  IIa-TM-TAFI1, 15, 54-56
Ia-TM + TAFI  IIa-TM-TAFI1, 15, 54-56
IIa-TM-TAFI  II-TM + aTAFI1, 15, 54-56
IIa-TAFI  IIa + aTAFI1, 15, 54-56
IIa-TAFI + TM  IIa-TAFI-TM1, 15, 54-56
IIa-TAFI-TM  IIa-TM + TAFI1, 15, 54-56
IIa-TAFI-TM  IIa-TAFI + TM1, 15, 54-56
aTAFI + Fm  aTAFI-Fm1, 15, 54-56
aTAFI-Fm  aTAFI-Fm + Lysine1, 15, 54-56
aTAFI  TAFIi1, 15, 54-56
IIa+ TAFI  IIa-TAFI1, 15, 54-56
IIa+ TAFI IIa-TAFI1, 15, 54-56
IIa-TM + TAFI  IIa-TM-TAFI1, 15, 54-56
Ia-TM + TAFI  IIa-TM-TAFI1, 15, 54-56
IIa-TM-TAFI  II-TM + aTAFI1, 15, 54-56
IIa-TAFI  IIa + aTAFI1, 15, 54-56
IIa-TAFI + TM  IIa-TAFI-TM1, 15, 54-56
IIa-TAFI-TM  IIa-TM + TAFI1, 15, 54-56
IIa-TAFI-TM  IIa-TAFI + TM1, 15, 54-56
IIa-TAFI-TM  IIa-TM + aTAFI1, 15, 54-56

TAFI
TAFI
TAFI
TAFI
TAFI
TAFI
TAFI
TAFI
TAFI
TAFI
TAFI
TAFI
TAFI
TAFI
TAFI
TAFI
TAFI
TAFI
TAFI
TAFI
TAFI
TAFI
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Appendix 3:

Agent

Initial
# of
Concentration
Agents
(microM)

I

8.83

883,000

II

1.4

140,000

V

0.02

2,000

VII

0.01

1,000

VIIa

0.0001

10

VIII

0.0003

30

IX

0.09

9,000

X

0.17

17,000

XI

0.025

2,500

XII

0.3

30,000

HMWK

0.9

90,000

PK

0.58

58,000

AT

3.4

340,000

TFPI

0.0025

250

Protein C

0.065

6,500
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Abstract
The coagulation system (CS) is a complex, inter-connected biological system with major physiological
and pathological roles. The CS may be viewed as a complex adaptive system, in which individual
components are linked through multiple feedback and feedforward loops. The non-linear relationships
between the numerous coagulation factors and the interplay among the elements of the CS render the
study of this biology at a molecular and cellular level nearly impossible. We present an Agent Based
Modeling and Simulation (ABMS) approach for simulating these complex interactions. Our ABMS
approach utilizes a subset of 52 rules to define the interactions among 33 enzymes and factors of the CS.
These rules simulate the interaction of each “agent”, such as substrates, enzymes, and cofactors, on a
two-dimensional grid of ~12,000 cells and ~300,000 agents.

Our ABMS method successfully

reproduces the initiation, propagation, and termination of thrombin formation due to the activation of the
extrinsic pathway. Furthermore, the ABMS is able to demonstrate the emergence of a threshold effect
for thrombin generation as a result of the synergistic effect of combining anticoagulant systems.

104

Introduction

Figure 1: Coagulation Cascade

Coagulation System In the event of an injury to the endothelium, the coagulation system balances the
need for localized clot formation against prevention of systemic activation. This finely tuned system is
composed of an assortment of molecular and cellular “agents” (e.g. substrates, enzymes, cofactors,
inhibitors, platelets, and endothelial cells) all interacting to generate a stable clot in order to rapidly
obtain hemostasis1. The new cellular model of hemostasis proposes that the classical pathways of
coagulation, i.e., the intrinsic and extrinsic pathways, mediate on specific cell surfaces in a tightly
regulated manner2-4. In this model, activation of factor VII (extrinsic, Fig. 1) and factor XII (intrinsic,
Fig. 1) results in the formation of the multi-molecular tenase and prothrombinase complexes, which
eventually generate thrombin. Thrombin then cleaves fibrinogen to form fibrin monomers, which
polymerize to form a three-dimensional clot.
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Clot formation is regulated in vivo through the antithrombin III-heparin complex (AT-H), activated
protein C (aPC), and tissue factor pathway inhibitor (TFPI) (Fig. 1). These regulating systems limit
excessive formation of cross-linked fibrin under hemostatic conditions. The anticoagulation systems are
regulated independently, but combine to synergistically control thrombin generation.

The CS may be viewed as a complex adaptive system, in which individual components are linked
through multiple feedback and feedforward loops.

These loops introduce non-linear relationships

among the components. A static diagram such as the classically portrayed coagulation pathway (Figure
1) cannot adequately describe this dynamic evolutionary network. More importantly, the effects of
several disease states on the imbalances in the CS are difficult to understand. Thus, the influence of
diseases that favor coagulation (e.g. myocardial infarction, disseminated intravascular coagulation,
cerebrovascular accidents, and venous thrombosis), or those that impair coagulation (e.g. hemophilias,
thrombocytopenias, and von Willebrand disease) remain poorly characterized.

Computational Modeling
Computational systems biology is an emerging field that provides tools to analyze and understand
complex adaptive systems such as the CS5,6. A major advantage of this approach is its rapid, real time
analysis of multiple biological systems; each may function as a highly coordinated independent network
interacting with other networks in the group at one or more branch points. These independent networks
can be thought of as small molecular machines, which work co-operatively to form a large, multicomponent molecular machine producing one or more physiological responses. Understanding the
mechanism and co-operativity of these networks as well as predicting the physiological response to
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appropriate pharmaceutical agents is an extremely difficult and intricate task. Yet, advanced systems
biology techniques, e.g., computational technology, may achieve this goal with consequent major
applications in understanding patho-physiological conditions and their treatment.
Table I: Entity Table
Entity
IX

VIII
VIIIa
VIIIa1

VIIIa2

IXa-VIIIa
IXa-VIIIa-X
VII
VIIa
II
IIa
X

V
Vi
Va-Xa
TF
TF-VIIa
AT
AT-Xa
AT-IXa
AT-IIa
AT-TF-VIIa

Description
Factor IX (Christmas factor)
Activates X. Forms tenase
complex
Factor VIII. Co-factor of IX –
Forms tenase complex
Activated factor VIII
Factor VIIIa spontaneously
dissociates into inactive VIIIa1 +
VIIIa2
Factor VIIIa spontaneously
dissociates into inactive VIIIa1 +
VIIIa2
tenase complex - activates X
IXa-VIIIa-X complex
Factor VII. Activates IX and X.
Activated factor VII
Factor II (prothrombin).
Activates F, V, VII, XIII
Activated factor II (thrombin)
Factor X. Activates II. Cofactor of V – forms
prothrombinase complex
Factor V. Co-factor of X –
forms prothrombinase complex
Inactivated V
Prothrombinase complex –
activates II
Tissue Factor. Activates X in
combination with VIIa
TF-VIIa complex
Antithrombin III – inhibits TFVIIa, IIa, IXa, XIa, XIIa and Xa
AT-Xa complex
AT-IXa complex
AT-IIa complex
AT-TF-VIIa complex
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TFPI
TFPI-Xa
TF-VIIa-XaTFPI
PC
aPC
aPC-Va
TM

IIa-TM

Tissue Factor Pathway Inhibitor
- inhibits VIIa-TF, Xa
TFPI-Xa complex
TF-VIIa-Xa-TFPI complex
Protein C – inactivates Va
Activated Protein C – activated
Protein C
aPC-Va complex
Thrombomodulin – In
combination with IIa, activates
PC
IIa-TM complex

To date, most computational models of the coagulation system have focused on using ordinary or partial
differential equations (ODEs and PDEs)7-9. Differential equations describe the change in the states of
the variables of the system over time and are derived from known or hypothesized kinetics. ODE
models can readily simulate coagulation in vitro as it is a relatively homogenous system10; however,
such models face significant limitations when modeling in vivo hemostasis due to complicating factors
such as non-stationarity, spatial heterogeneity and the effects of blood flow. Therefore, derivation of
differential equations suitable for in vivo modeling becomes problematic.

In order to address the shortcomings associated with ODE models, we present the application of a
computational systems biology approach using agent-based modeling and simulation (ABMS) to
understand the CS and determine the role of coagulation inhibitors in preventing complete activation of
thrombin. ABMS provides a powerful alternative to differential equations11-13. ABMS is a relatively
new modeling paradigm derived from cellular automata (CA)14,15. ABMS has mobile autonomous
entities (agents) that can move through space. Each agent is allowed to assume a finite number of states,
determined by a pre-defined set of rules. Every agent is individually updated at the end of each operating
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period according to the pre-set rules. The rules are a function of the current state of the agent and the
state of its neighbors.

Coagulation Model
Table II: Rule Table
#
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
23
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

Reaction
VII + TF  VII-TF7,19-21
VII + TF  VII-TF7,19-21
VIIa + TF  VIIa-TF7,19-21
VIIa + TF VIIa-TF7,19-21
VIIa-TF + VII  VIIa-TF + VIIa7,8,22
Xa + VII  Xa + VIIa7,8,22
IIa + VII  IIa + VIIa7,8,22
VIIa-TF + X  VIIa-TF-X7,21,23
VIIa-TF + X  VIIa-TF-X7,21,23
VIIa-TF-X  VIIa-TF + Xa7,24,25
VIIa-TF + Xa  VIIa-TF-Xa7,25,26
VIIa-TF + Xa  VIIa-TF-Xa7
VIIa-TF + IX  VIIa-TF-IX7,27,28
VIIa-TF + IX  VIIa-TF-IX7,27,28
VIIa-TF-IX  VIIa-TF + IXa7,27,28
VIIIa + IXa  VIIIa-IXa7,28
VIIIa + IXa  VIIIa-IXa7,28
VIIIa-IXa + X  VIIIa-IXa-X7,28,29
VIIIa-IXa + X  VIIIa-IXa-X7,28,29
VIIIa-IXa-X  VIIIa-IXa-Xa7,28,29
VIIIa  VIIIa1 + VIIIa27,30
VIIIa  VIIIa1 + VIIIa27,30,31
VIIIa-IXa  VIIIa1 + VIIIa2 + IXa7,32
Xa + II  Xa + IIa7,8,33,34
IIa + VIII  IIa + VIIIa7,8,23
IIa + V  IIa + Va7,8,28,35,36
Xa + Va  Xa-Va7,28
Xa + Va  Xa-Va7,28
Xa-Va + II  Xa-Va-II7,28
Xa-Va + II  Xa-Va-II7,28
Xa-Va-II  Xa-Va + IIa7,28
Xa + TFPI  Xa-TFPI7,23,28
Xa + TFPI Xa-TFPI7,23,28
TF-VIIa-Xa + TFPI  TF-VIIa-Xa-TFPI7,23,37

Pathway
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Extrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Intrinsic
Common
Common
Common
Common
Common
Common
Common
Common
TFPI
TFPI
TFPI
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43
44
45
46
47
48
49
50
51
52

TF-VIIa-Xa + TFPI  TF-VIIa-Xa-TFPI7,23,37
TF-VIIa + Xa-TFPI  TF-VIIa-Xa-TFPI7,23,37
AT + Xa  AT-Xa7,8,38
AT + TF-VIIa  AT-TF-VIIa7,8,33
AT + IXa  AT-IXa7,8,38,39
AT + IIa  AT-IIa7,8,40
PC + IIa  aPC + IIa17
IIa + TM  IIa-TM17
PC + IIa-TM  aPC + IIa-TM17
aPC +Va  aPC + Vi 17

TFPI
TFPI
AT
AT
AT
AT
aPC
aPC
aPC
aPC

The model described in this paper is designed to simulate thrombin formation in the in vitro
environment. Therefore, a limited subset of substrates, reactions, and products from the intrinsic,
extrinsic, common, AT-H, TFPI, and aPC pathways have been included (Table I & II). In order to
create realistic simulations, physiologic concentrations of factors were used in the in silico experiments
(Table III). The rates associated with the reactions were taken from the literature and were assumed to
be performed in saturating phospholipid and calcium conditions. The simulations were designed to test
experimental conditions that create thrombin profiles reflective of the threshold phenomena associated
with physiologic concentrations of coagulation inhibitors.

Table III: Baseline plasma concentration of coagulation factors.
Agent

Initial
Concentration
(µM)
TF-VIIa Varies
II
1.4
V
0.02
VII
0.01
VIIa
0.0001
VIII
0.0003
IX
0.09
X
0.17
AT
3.4
TFPI
0.0025

# of
Agents
Varies
280,000
4,000
2,000
20
60
18,000
34,000
68,000
500
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PC
TM

0.065
Varies

13,000
Varies
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Materials and Methods

Coagulation Model
The ABMS in this paper uses a two dimensional particle system whereby particles move freely and
interact on a discrete spatial grid. In this specific model, we define the particles of the system as the
reactants, enzymes, and products in the entity table (Table I).

The spatial grid is set as a two

dimensional grid where the agent‟s location is identified by its x and y coordinates. Each coordinate
pair (x, y) delineates a unique location. The number of grid locations used in these simulations is
12,321. The number of agents in the simulations is on the order of 300,000. Each time step of the
simulation represents 0.01 seconds.

Grid locations in this model are designated as either empty or occupied by one or more substrates,
enzymes, or reaction products. The agents are allowed to move freely about the grid. The movement,
joining, and breaking are governed by probability rules. The movement parameter determines the extent
of each agent‟s motion (0 implies every cell is stationary). The joining parameter determines the extent
of interaction between adjacent agents. The breaking parameter defines the extent of disruption of
agents that have joined. This model sets the probability of joining and breaking based on experimentally
determined kinetic constants. The movement parameter is set at 1. The agents are allowed to interact
with all their neighbors, but meaningful interactions are limited to those in the rule table (Table II). The
neighborhood of each agent in this model is defined as all agents located in the same grid location.
After each time step, the agents move in a random manner to an adjacent grid location.

ABMS modeling requires the assignment of the probability of conversion associated with each chemical
reaction as defined in the rule table (Table II). Reductionist in vitro experimental techniques have
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allowed a detailed understanding of the individual chemical reactions involved in the process of
coagulation. The information obtained by studying the individual reactions is used as the basis for the
rules governing the updating of the ABMS at each time step. We assigned a probability of conversion
value related to the kinetics of the reactions. The initial configuration is random; each substrate and
enzyme is assigned a predefined number of agents based on their desired initial concentration (Table
III).

In vivo, prothrombinase and tenase complexes are formed through a combination of three factors. The
prothrombinase complex is formed by a combination of prothrombin, factor Xa and factor Va; the
intrinsic tenase complex is formed when factors VIIIa and IXa combine with factor X. These three-body
complexes are not directly simulated in ABMS, as in vivo, they must arise through sequential
combination of two molecules. Thus, we utilized a sequential two-body collision approach to generate
each complex.

The ABMS is designed to represent the in vitro environment. In this case, the spatial grid is in the shape
of a rectangle allowing the particles to interact and bounce off the edge of the grid. There are no
platelets, RBC, or WBC in the system as in vitro coagulation tests are run on acellular plasma.

Computation
Netlogo v4.04, a software package designed to run ABMS, was utilized to perform the simulations 16.
The user determines the subset of reactants, the subset of reactions, the subset of coagulation factors,
rate constants, initial factor concentrations, and termination conditions for each simulation.

The

concentration of every coagulation factor was output every 100 time steps (1 virtual second). The
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output of each simulation was stored in a comma separated file. All simulations were carried out on an
Intel based desktop personal computer running Microsoft Windows XP. Up to six simulations were run
in parallel.

Each simulation ran up to 72 hours depending on the initial and stop conditions.

Simulations were terminated after 90,000 iterations if the terminating conditions were not met.

Simulations
Unless otherwise stated, modeling of the system was performed under conditions that simulated
literature derived mean physiologic concentrations of each soluble factor in normal humans (Table 3).
The simulations were designed to determine the effects of coagulation inhibitors on thrombin (IIa)
generation profiles. Comparisons between the ABMS output and experimental data determined the
validity of the system.

Results
The threshold dependent formation of IIa in the presence of inhibitors such as AT, PC, and TFPI is an
important feature of the coagulation system. Figure 2, demonstrates this characteristic profile that results
as a function of the combination of AT and TFPI. At low concentrations of TF-VIIa (5pM), the
threshold value required for production of IIa is not reached; whereas both 30pM and 130pM
concentration were able to generate a short burst of thrombin. These results demonstrate the synergistic
effect of inhibitors (AT and TFPI) on the extrinsic system. The combination of AT and TFPI results in
the creation of a threshold concentration of TF-VIIa (between 5pM and 30pM). Below this threshold
value significant amounts of thrombin are not generated.
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The combination of PC and TFPI results in the threshold demonstrated in Figure 3. The experiments
were initiated by TF-VIIa at 5pM. With no TM, all of the prothrombin (II) is converted to thrombin;
whereas at concentrations of 0.1nM TM and 10nM TM, generation of thrombin is quenched. In this

Figure 2: Thrombin generation as a function of TF-VIIa concentration in the presence of TFPI and AT. The
experiments were conducted with 2.5 nM TFPI and 3.4uM AT. The initiating concentrations of TF-VIIa are 130pm
(circles), 30pM (triangles), and 5pM (squares). N=5.

case, the threshold is a function of TM concentration. Thus, a bifurcation point exists between 0nM and
0.1nM of TM whereby PC in combination with TFPI prevents the burst of thrombin generation.

Figure 4 demonstrates the effects of combining AT and PC. At concentrations of 5pM of TF-VIIa no
thrombin was generated (data not shown). At initial concentrations of 30pM TF-VIIa, the characteristic
bell shaped curve is observed with no TM and 0.1nM TM. At 10nM concentrations of TM, the burst of
thrombin is suppressed.

In figure 5, all three inhibitors are utilized. No thrombin is generated when initialized with 5pM or
30pM of TF-VIIa (data not shown). At 130pM of TF-VIIa, a burst of thrombin is observed with low
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Figure 3: Thrombin generation as a function of TM concentration in the presence of TFPI and Protein C.
The experiments were conducted with 2.5 nM TFPI and 65 nM Protein C. The initiating concentration of TF-VIIa is
5nM. The TM concentrations 0 (circles), 0.1 nM (triangles), and 10nM (squares). N=5.

TM concentrations (no TM and 0.1nM TM), but is suppressed at 10nM TM.

Figure 4: Thrombin generation as a function of TM concentration in the presence of AT and Protein C. The
experiments were conducted with 3.4 µM AT and 65 nM Protein C. The initiating concentration of TF-VIIa is 30nM. The
TM concentrations are 0 (circles), 0.1nM (triangles), and 10nM (squares). N=5.
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Figure 5: Thrombin generation as a function of TM concentration in the presence of TFPI, AT, and Protein C. The
experiments were conducted with 2.5 nM TFPI , 3.4 µM AT, and 65 nM Protein C. The initiating concentration of TF-VIIa
is 130nM. The TM are 0 (circles), 0.1 nM (triangles), and 10nM (squares). N=5.

Discussion
The components of the CS interact strongly at the molecular and cellular level; they thereby operate as a
coherently linked system that generates both pathological and physiological responses. The highly
complex CS presents a challenging problem of identifying the root cause of many known coagulation
defects. To date the contribution of each system as a part of the network has not been attempted. We
have developed an ABMS of the CS cascade that allows systematic evaluation of each of its components
– individually and as a complex entity. The model allows a comprehensive analysis of the CS cascade
that provides insight into understanding and predicting the pathophysiologic responses arising from
variations in its molecular and cellular components.

Only by creating models, which account for these seemingly diverse but clearly connected processes can
one hope to improve our overall understanding of the coagulation process and to create more powerful
diagnostic and therapeutic options. We have employed an ABMS in our current approach due to the
potential ability to quantitatively analyze individual components of each system at every point of
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simulation. ABMS is a dynamic modeling and simulation tool that allows the study of dynamic nonlinear networked systems. ABMS represents a non-reductionist approach of studying the biologic
process as a whole, while retaining the information at an individual level. The complexity of the system
has stymied experimental efforts to gain a system level understanding of the coagulation cascade and its
subnetwork components. ABMS may readily provide elucidation of the pathophysiology of diseases
related to the coagulation system. The model may prove informative regarding individual disease
processes such as genetic and acquired disorders of coagulation.

The initial results of this paper indicate that the in vitro coagulation system can be readily simulated
using ABMS. Our ABMS approach successfully reproduces the initiation, propagation, and termination
of thrombin formation in vitro. Furthermore, the ABMS was able to simulate the threshold effect of
thrombin formation resultant from the synergistic relationship between physiologic concentrations of
coagulation inhibitors.

This suppression of thrombin is the likely mechanism behind localization of the

hemostasis response. The mechanism demonstrated herein provides the rationale for localized
formation of a blood clot at the site of endothelial injury as opposed to a systemic vascular thrombotic
response. Presumably, the thrombin concentrations upstream and downstream of the endothelial injury
fail to reach self sustaining levels due to the synergistic effects of AT, TFPI, and aPC. A possible
therapeutic strategy of manipulating coagulation inhibitors for the treatment of diseases involving the
systemic activation of the CS, such as trauma induced coagulopathy (TIC), disseminated intravascular
coagulopathy (DIC), coagulopathy associated with cardiac arrest, etc…, is suggested by the findings in
this paper.

The next step in the progression of our coagulation model is to simulate the in vivo environment.
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Expansion of the model will require the addition of blood flow, endothelial cells, white blood cells,
platelets, and the full complement of coagulation proteins. Such a model will provide insight into
complex disease processes that are impossible to obtain using laboratory techniques. Computational
systems biology allows the design and implementation of experiments that would be unethical and
dangerous in the clinical setting; instead, creation of previously unavailable diagnostic and therapeutic
strategies becomes possible.

ABMS allows a real time analysis of the coagulation system that cannot be obtained through in vivo
experiments. Additionally, ABMS provides an opportunity to understand the complex interplay among
the various subsystems. The advantages of ABMS include the ability to simulate the non-linear aspects
of the coagulation system. Moreover, the model is flexible and able to account for changes such as lack
of inhibitors, absence of factors, or therapeutic interventions associated with disease processes. As new
mediators are discovered they are easily added to the model.

Another major advantage of ABMS is the ability to monitor each coagulation factor as „clotting‟
proceeds. This implies that the effect of a large number of factors that influence coagulation (e.g.
natural and pharmaceutical anticoagulants, natural and pharmaceutical fibrinolytic agents, and intrinsic
and external inflammation mediators) can be simulated readily. These ABMS are expected to provide
information regarding the overall progress of clotting as well as individual coagulation factors as a
function of time. Thus, ABMS of the coagulation cascade affords the ability to simulate the effect of
heparins / low molecular weight heparins, coumadins, and factor Xa / thrombin inhibitors at a systemic
level for the first time.
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The last and most important advantage of the model is it is capable of exhibiting emergent behaviors in
which its outputs produce unanticipated results, which can then be biologically confirmed. Such
properties are particularly useful in the discovery of diagnostic and therapeutic interventions.
Comprehensive modeling of the traditional coagulation

cascade allows unlimited virtual

experimentation on the effects of local and systemic injury on coagulation.

The time required to update the model is one disadvantage of ABMS as it is computationally expensive
for large systems with many elements. Conversion of the model into other platforms may provide
significantly decrease the time required to run simulations. For example, the model can be moved to an
alternate ABMS platform (I.E. Repast) with an expected halving of the execution time. Ultimately,
conversion of the model into a format that can be run on graphical processing units (GPU) may allow
significant decreases in execution time (on the order of 100x) that could allow simulations to be run at a
patient‟s bedside in real-time.

Computational modeling allows the creation of rapid and inexpensive virtual laboratories to generate
and test hypotheses. More importantly, simulations provide clinical tools to design and test novel
therapeutic strategies, while affording opportunities to predict adverse events during drug development.
Additionally, bedside simulations will allow personalized medicine to calculate replacement factor
concentrations for individual hemophiliac patients, heparin doses can be titrated, etc…

Future

applications of the model include discovery of new mediators, understanding of proximal and distal
effects of interactions between systems, discovery of new diagnostic and therapeutic options, and
development of new software and algorithms for simulation.
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Future Directions
The next step in the progression of our coagulation model is to simulate the in vivo environment.
Expansion of the model will require the addition of blood flow, endothelial cells, white blood
cells, platelets, and the full complement of coagulation proteins. Such a model will provide
insight into complex disease processes that are impossible to obtain using laboratory techniques.
Computational systems biology allows the design and implementation of experiments that would
be unethical and dangerous in the clinical setting; instead, creation of previously unavailable
diagnostic and therapeutic strategies becomes possible.

The time required to update the model is one disadvantage of ABMS as it is computationally
expensive for large systems with many elements. Not only does this necessitate long
development times, but limits the use of the model to offline situations. Conversion of the model
into other platforms may provide significantly decrease the time required to run simulations and
increase its utility as a clinical tool. For example, the model can be moved to an alternate
ABMS platform (I.E. Repast) with an expected halving of the execution time. Ultimately,
conversion of the model into a format that can be run on graphical processing units (GPU) may
allow significant decreases in execution time (on the order of 100x) that could allow simulations
to be run at a patient’s bedside in real-time.

TIC: A Computational Model of In Vivo Trauma Induced Coagulopathy*
Objective: The PULSE initiative identified prevention of diffuse coagulopathies to be a priority
in resuscitation science. Trauma Induced Coagulation (TIC) is a significant complication of
* Presented at the 2008 American Heart Association Annual Meeting, and was awarded the
young investigator award.
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trauma involving the complex nonlinear interplay of the coagulation and inflammation system
(CIS). Its complexity poses significant challenges for systematic clinical study. Modeling via
computational approaches may prove to be a valuable adjunct. We developed a model of TIC
using a 2-D Agent Based Model (ABM).

Methods: A 2-D particle system was developed in which particles move and interact on a
discrete spatial grid composed of ‘cells’. The particles of the system are cells (endothelial, WBC,
platelets), reactants, enzymes, and reaction products. The number of ‘cells’ used in the
simulations is 1,000,000 with a coagulation factor density of 16%. The particles’ actions are
determined by a set of rules derived from coagulation kinetics and cell behaviors. The system is
designed to model a blood vessel in vivo including blood flow. The model is perturbed by
alterations in systemic variables (temperature, pH, coagulation factor concentration,
oxygenation).

Results: The effects of temperature, pH, and coagulation factor dilution were synergistic on the
model resulting in increased INR values ranging from 1.5 to 7.76. A state of anti-coagulation and
hyperfibrinolysis existed independent of temperature and pH. Endothelial cell activation from
hypovolemia resulted in the increased expression of TM, TFPI, and tPA with a concomitant
decrease in PAI. This resulted in a state of anticoagulation from the diversion of thrombin to the
activation of PC (by binding to thrombin) combined with increased TFPI. Increased levels of
tPA combined with decreases in PAI result in a state of hyperfibrinolysis that dissolves any clot
formed in the anti-coagulation environment.
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Conclusion: The simulation indicates that the effects of trauma on the CIS can be readily
simulated. The ABM successfully modeled TIC seen in vivo due to endothelial cell activation
from hypoperfusion as supported by the literature. The ABM will be used to target mediator
levels for clinical verification as well as to develop preclinical and clinical testing of therapies
that may modulate the CIS to enhance outcomes.

DIC: A Computational Analysis of the Coagulopathy Associated with Disseminated
Intravascular Coagulopathy*

Objective: The PULSE initiative identified prevention of diffuse coagulopathies to be a priority
in resuscitation science. Disseminated Intravascular Coagulopathy (DIC) is a significant
complication of diseases such as sepsis and cancer. DIC involves the complex nonlinear
interplay of the coagulation, fibrinolytic, and inflammatory systems (CIF). Its complexity poses a
significant challenge for systematic clinical study; thus, modeling via computational approaches
may prove to be a valuable adjunct. We developed a model of DIC using a 2-D Agent Based
Model (ABM) implemented in the Netlogo modeling platform.

Methods: A 2-D particle system was developed in which particles move and interact on a
discrete spatial grid composed of ‘cells’. The particles of the system are cells (endothelial, WBC,
platelets), cytokines, reactants, enzymes, and reaction products. The number of ‘cells’ used in the
simulations is 5041 with approximately 500,000 agents. The agents’ actions are determined by a
set of rules derived from coagulation kinetics and cell behaviors. The system is designed to
model a blood vessel in vivo including blood flow. The grid is in the shape of a rectangle. The
* Presented at the 2009 Annual SwarmFest.
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sides of the rectangle represent endothelial cells and allow agents to interact with the endothelial
cells or bounce off the walls. The ends are empty and allow the loss and introduction of agents.
Blood flow is simulated by pulsatile movement of the particles through the system. The model is
perturbed by the introduction of elevated levels of TNF-α in order to simulate the systemic
inflammatory response from an insult such as sepsis.

Results: The simulation represents the formation of DIC due to elevated levels of TNF-α and
subsequent activation of the inflammatory system. The activation of the coagulation system
leads to the formation of microvasculature clot formation and a consumptive coagulopathy that
results in the impairment of hemostasis. Table 1 demonstrates the alteration in the plasma levels
of Antithrombin III (AT), Fibrinogen (F), platelet (plt), and Fibrin Split Products (FSP). As can
be expected, the levels of AT, F and plts decrease as they are consumed by the systemic
activation of the coagulation system, and the levels of FSP continue to increase as the clot is
continually dissolved by the fibrinolytic system.

Conclusion: The simulation indicates that the effects of systemic inflammation on the CIF can
be readily simulated using ABM. The ABM effectively modeled DIC as the end product of
elevated cytokine levels as may be seen in sepsis. The demonstrated parameters and resultant
coagulopathy are consistent with clinical DIC found in the literature. The goal in creating an
ABM of DIC is to develop preclinical and clinical testing of therapies that may modulate the CIF
to enhance patient outcomes.

Time (h)

AT (µM)

Fibrinogen (µM)

Platelet (x 109)

FSP(µg/mL)
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0

4.50

88.20

300

0.0

1

4.37

83.74

291

0.3

4

3.65

74.91

271

2.7

8

2.74

64.29

227

6.0

12

1.80

29.63

39

33.5

16

1.07

22.06

11

37.5

Table 1: Plasma levels of AT, F, Plt, and FSP in DIC

Cardiac Arrest: A Computational Model of the Effect of Cardiac Arrest on the
Coagulation System*

Objective: The PULSE initiative identified prevention of diffuse coagulopathies to be a priority
in resuscitation science. Coagulopathy is a potential significant complication of cardiac arrest
that involves the complex nonlinear interplay of the coagulation and inflammation system (CIS).
This complexity has made it difficult to study it in an integrative fashion at the microvessel level
in cardiac arrest. We developed a 2-D Agent Based Model (ABM) to begin to better understand
the CIS in cardiac arrest.

Methods: The ABM utilizes a 2-D particle system. Particles move and interact on a discrete
spatial grid. The particles of the system are the cells, reactants, enzymes, and reaction products.
The system is designed to model a blood vessel in vivo. The grid is in the shape of a rectangle.
The sides of the rectangle represent endothelial cells; particles are capable of interacting with the
endothelial cells. In a steady state, blood flow was suddenly discontinued for 20 minutes
followed by return of spontaneous circulation (ROSC) for another 20 minutes. The levels of
circulating coagulation factors and their products and function were continually monitored.
* Presented at the 2008 American Heart Association Annual Meeting.
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Results: After 20 minutes of no flow, we observed a state of hypercoagulability, impaired
fibrinolysis, and systemic microthrombi formation consistent with post-arrest clinical studies in
the literature. Endothelial cell response to hypoxia results in elevated levels of TAT and fibrin
monomers consistent with activation of the coagulation system. Concomitant lack of D-dimer
and FSPs demonstrated the decreased expression of TM, TFPI, and tPA. Following ROSC, the
activation of the anticoagulation system and pro-inflammatory mediators resulted in a disruption
of the equilibrium between the coagulation, anti-coagulation, fibrinolytic and inflammatory
systems consistent with a clinical state of low grade DIC. This was also consistent with the
literature.

Conclusions: The ABM model simulates the effects of cardiac arrest on the CIS and may be
useful for studying arrest induced CIS changes as well as what affects various interventions such
as hypothermia may have. Data obtained will be used to target mediator levels for verification as
well as to design studies that may modulate the CIS to improve outcomes.

GPU based: Utilizing GPU Computing to Analyze Complex Biological Systems*
The coagulation system (CS) is a complex, inter-connected biological system with major
physiological and pathological roles. The CS may be viewed as a complex adaptive system,
through which multiple feedback and feed-forward loops link its individual components. Nonlinear relationships between the numerous coagulation factors render the study of this biology at
a molecular and cellular level nearly impossible. We have employed an Agent Based Modeling
Simulation (ABMS) in our current approach to the analysis of the CS. One of the most

* Submitted to the 2010 ACM International Conference on Bioinformatics and Computational
Biology
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significant drawbacks to using ABMS is the computational expense associated with large
systems.

To date, our efforts to successfully model the CS have been stymied by the time required to run
simulations. The large number of elements (on the order of 106) requires days to weeks to run
basic simulations. We hypothesized that conversion of the model into other platforms may
significantly decrease this time. We present a comparison of the run-times of 4 ABMS models: 1
& 2) common platforms Netlogo and Repast; 3) C program designed to run on a single
processor and 4) C program designed to utilize the parallel architecture of the Graphics
Processing Unit (GPU). As expected, it is observed that GPU-based execution affords
significant improvement (on the order 103) over the conventional ABMS platforms on the
runtimes of our complex CS model.

GPU computing provides the opportunity to obtain near supercomputer performance on a
desktop computer. The use of this virtual supercomputer can fuel complex systems analysis
without the need for costly high performance computing resources. Our results indicate that
complex models of the human CS can be implemented using GPU based computing with
significant gains in performance. The use of such models will allow the creation of rapid and
inexpensive virtual laboratories that can be used to generate and test hypotheses and provide
clinical tools to design and test novel therapeutic strategies.
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Summary
By definition, a complex system exhibits emergent and self organized behaviors. They typically
involve many heterogeneous components that interact in a nonlinear manner usually involving
feedforward and feedback loops which are used to amplify or dampen signals. Complex systems
are bound by their components. Through production and utilization of information from their
internal and external environments, these components collectively give rise to complex,
changing patterns and behaviors. As a result, unique properties emerge. These properties lead to
a common definition of complex systems: a large number of simple components with simple
behavior that gives rise to complex collective behavior despite the lack of an overlying controller
and sophisticated information processing and adaptation.

The complex behavior that arises from such systems is called emergent behaviors. If the
organized behavior occurs despite the lack of a controller, the system is labeled “self-organizing”
Complex systems are ubiquitous through the natural world. Analysis of complex systems
requires interdisciplinary measures to describe these sophisticated systems. Computational
modeling offers an attractive in silico approach to such analysis.

Computational systems biology is a rapidly growing field that provides tools to analyze and
understand dynamic evolutionary networks. A major advantage of this approach is its rapid, real
time analysis of overlapping biological systems, each of which can be a highly coordinated
independent network interacting with other networks in the group at one or more branch points.
These independent networks can be thought of as small molecular machines, which work cooperatively to form a large, multi-component molecular machine producing one or more
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physiological responses. Understanding the mechanism and co-operativity of these networks as
well as predicting the physiological response to appropriate pharmaceutical agents is an
extremely difficult and intricate task. Advanced systems biology techniques, e.g. computational
technology, hold major promise in achieving this goal and consequently may be extremely useful
in understanding patho-physiological conditions and their treatment.

In order to develop useful integrative systems biology approaches, computational tools integrate
complexity theory to predict responses of relevant processes to interventions. Mathematical
models represent one such method. The failure of animal models to accurately predict the
usefulness of therapies and the difficulty of enrolling large numbers of human subjects in studies
has been a major roadblock in the study of complex diseases. Mathematical models offer a noninvasive intermediary step that allows hypothesis and therapies to be tested prior to clinical
studies. Thus, an in silico model would potentially increase the success rate of clinical trials or
aid in designing more appropriate animal studies. Manipulation of the model would then provide
direction to the subsequent methodologies necessary to take the next steps in discovery. These
animal or clinical studies would then in turn, validate the model.

Ideally, a well-constructed computational model will offer a rapid and inexpensive virtual
laboratory to simulate the effects of biological hypotheses prior to testing these theories in vitro
or in vivo[77]o. Accurate predictions by any model, from cell cultures to in vivo animal models
to mathematical models, are dependent on the accuracy of the relation between the model and the
corresponding real-world process. They are highly dependent on certain data imputations that are
derived from animal data, clinical results, or assumptions based on observations or general
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agreements within the community studying the disease. Such models require extensive
validation; however, it will eventually provide insight into processes that are initially difficult to
observe in an intact system. Thus, a successful computational model will not only fill the gaps in
our knowledge, it will also identify previously unrecognized gaps as well.

In addition to the benefits associated with theoretical advances, simulations provide clinical tools
to design and test novel therapeutic strategies, while affording opportunities to predict adverse
events during drug development. Bedside simulations will allow personalized medicine in that
replacement factor concentrations can be calculated for individual hemophiliac patients, heparin
doses can be titrated, etc… Other applications of the model include discovery of new mediators,
understanding of proximal and distal effects of interactions between systems, discovery of new
diagnostic and therapeutic options, and development of new software and algorithms for
simulation.

Normal wound healing is a carefully choreographed process that results in a mature scar, which
restores the anatomic and functional integrity of the dermis[25]. The process is divided into an
orderly progression of individual phases. The hemostatic phase is controlled by platelets, which
ensure wound stabilization and recruits inflammatory cells into the wounded tissue. The
inflammatory phase, which is initially dominated by neutrophils and subsequently by
macrophages, prepares the wound bed by killing bacteria and removing devitalized tissue as well
as recruiting fibroblasts. The proliferative phase is characterized by fibroblasts laying down a
provisional ECM matrix. The remodeling phase is a balance of collagen synthesis and
degradation that results in a mature scar that maximizes wound tensile strength. The complexity
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of acute wounds have stymied clinical investigators. Computational biology shows promise in
providing an alternative avenue of study for wound healing.

We have modified an ODE model of the acute systemic response to inflammation a soft tissue
injury. Our model includes factors such as bacterial contamination and wound oxygenation.
Assuming normal conditions, our model predicts the typical progression of healing behavior for
a wound. The ODE model was also able to successfully simulate the impairment in wound
healing found in a hypoxic wound environment and a contaminated wound. For example, under
hypoxic conditions, we observe a non-healing wound where the damage persists despite the
absence of pathogens. With extremely low levels of oxygen our model predicts a chronic
infection where the wound does not heal and pathogens persist in the wound. Both of these
states are well documented clinically.

We also examined the situation of elevated and depressed fibroblasts mortality rates. Clinically,
instances of elevated fibroblast mortality are seen in diabetic and elderly patients. We observed
non-healing wounds in the context of high rates of fibroblast mortality. Additionally, a scenario
of moderately low fibroblast mortality and high initial pathogen levels predicts the state of
chronic infection. Finally, we examined the case where fibroblast production is either impaired
or enhanced. Impaired fibroblast production results in a non-healing state; however with an
increase in production, wounds heal at notably faster rates. This provides a framework from
which to test a new hypothesis in a living model, i.e. improve fibroblast production in an effort to
increase wound healing rates.
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Our model successfully simulated results typical of hypoxic wound environments with
significant bacterial contamination. Though most of our results are not overly surprising, we are
satisfied and encouraged that our model is qualitatively accurate in its predictions of real
systems. This provides some level of model calibration. Translation of our model to the level of
clinical relevance will require an enormous number of important variables both at the local and
systemic levels. We are now in the process of examining systemic mediators and their effects on
healing at the local environment. This includes hormonal differences thus taking into account
gender differences and the effects of systemic inflammation.

Another difficult clinical problem is that of diseases associated with coagulation and fibrinolysis.
Coagulation is a complex process by which blood forms solid clots. It is an important part of
hemostasis defined as the cessation of blood loss from a damaged vessel. A damaged blood
vessel wall is covered by a platelet- and fibrin-containing clot to stop bleeding. Coagulation is
initiated almost instantly after an injury to the blood vessel damages the endothelium (lining of
the vessel). Fibrinolysis is a complex process by which pre-formed clot is proteolitically
degraded once the underlying endothelial injury has been repaired. The CF systems interact
strongly at the molecular and cellular level; they thereby operating as a coherently linked system,
to generate several pathological and physiological responses. The highly complex CF system
presents a challenging problem of identifying the root cause of many known coagulation defects.
To date the contribution of each system as a part of the network has not been attempted.
Furthermore, the difficulties in studying a system that has the following properties:
nonstationarity, spatial heterogeneity, and blood flow. The CF system also can be defined as a
complex system: 1) large number of heterogenous components (zymogens, enzymes, cofactors,
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inhibitors, membranes, and cells), 2) no overlying controller (the CF reactions are all local and
based on molecular interactions), 3) non-linear (the biochemical reactions among the
components are all non-linear), and 4) emergence (threshold effects for thrombin generation,
localized clot formation, and delayed clot lysis). Given the difficulties associated with the study
of the CF system, the study of such a complex system may benefit from computational analysis.

We have developed an ABMS of the CF cascade that allows systematic evaluation of each of its
components – individually and as a complex entity. The model allows a comprehensive analysis
of the CF cascade that provides insight into understanding and predicting the pathophysiologic
responses arising from variations in molecular and cellular components. ABMS allows a real
time analysis of the CF systems that is difficult if not impossible to obtain through in vivo
experiments. Additionally, ABMS provides an opportunity to understand the complex interplay
among the various subsystems at any point in time. Reductionist in vitro experimental
techniques have allowed a detailed understanding of the individual chemical reactions involved
in the process of coagulation. ABMS represents a non-reductionist approach of studying the
biologic process as a whole, while retaining the information at an individual level. The
information obtained by studying the individual reactions is used as the basis for the rules
governing the updating of the ABMS. The advantages of ABMS include the ability to simulate
the non-linear aspects of the coagulation system. As the agents are able to change state based on
their environment, the model adapts and accounts for changes such as dearth/excess of
coagulation inhibitors, absence of factors, or therapeutic interventions. The time required to
update the model is one disadvantage of ABMS as it is computationally expensive for large
systems with many elements; however a specific advantage of this model is its ability to allow
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for the addition of newly discovered mediators, which can impact upon both coagulation and
inflammation. More importantly, the model has a high probability of exhibiting emergence in
which its outputs produce unanticipated results, which can then be biologically confirmed. Such
properties are particularly useful in the discovery of diagnostic and therapeutic interventions.
Comprehensive modeling of the traditional coagulation cascade allows virtual experimentation
of the effects of local and systemic injury on coagulation.

The in vitro CF system can be readily simulated using ABMS. Our ABMS approach
successfully reproduces the initiation, propagation, and termination of thrombin formation in
vitro. Furthermore, the ABMS was able to simulate the threshold effect of thrombin formation
resultant from the synergistic relationship between physiologic concentrations of coagulation
inhibitors.

This suppression of thrombin is the likely mechanism behind localization of the

hemostasis response. The mechanism demonstrated herein provides the rationale for localized
formation of a blood clot at the site of endothelial injury as opposed to a systemic vascular
thrombotic response. Presumably, the thrombin concentrations upstream and downstream of the
endothelial injury fail to reach self sustaining levels due to the synergistic effects of AT, TFPI,
and aPC. A possible therapeutic strategy of manipulating coagulation inhibitors for the treatment
of diseases involving the systemic activation of the CS, such as TIC, DIC, coagulopathy
associated with cardiac arrest, etc…, is suggested by the findings in this paper. The model also
successfully simulated aPTT and PT times at normal physiologic conditions, abnormal
physiologic conditions (hemophilia B and AT-H binding defect), and after pharmaceutical
interventions (warfarin and heparin). The non-linearities of the CF system were captured using
this ABMS. The ability to generate results similar to those obtained experimentally has been
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demonstrated. The error bars associated with the data are unique to ABMS and provide the
ability to simulate experiments and clinical trials.

The next step in the progression of our coagulation model is to simulate the in vivo environment.
Expansion of the model will require the addition of blood flow, endothelial cells, white blood
cells, platelets, and the full complement of coagulation proteins. Such a model will provide
insight into complex disease processes that are impossible to obtain using laboratory techniques.
Computational systems biology allows the design and implementation of experiments that would
be unethical and dangerous in the clinical setting; instead, creation of previously unavailable
diagnostic and therapeutic strategies becomes possible.

The time required to update the model is one disadvantage of ABMS as it is computationally
expensive for large systems with many elements. Conversion of the model into other platforms
may provide significantly decrease the time required to run simulations. For example, the
model can be moved to an alternate ABMS platform (i.e. Repast) with an expected halving of the
execution time. Ultimately, conversion of the model into a format that can be run on graphical
processing units (GPU) may allow significant decreases in execution time (on the order of 100x)
that could allow simulations to be run at a patient’s bedside in real-time.
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